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                                                                    Abstract 
Protein-based pharmaceuticals are a fast growing class of therapeutics, which are widely used in 
the treatment of various diseases such as cancers and autoimmune diseases. Proteins are 
susceptible to multiple degradation pathways including oxidation, deamidation and 
photodegradation. Over the past decade, the pharmaceutical industry has become increasingly 
cognizant of the sensitivity of proteins towards light. The exposure of proteins to light during 
their development and patient administration is inevitable, and may result in protein degradation. 
In the recent past there have been multiple reports indicating formation of aggregates, 
discoloration, oxidation, covalent crosslinking and fragmentation on exposure of protein 
pharmaceuticals to light. These degradation pathways could enhance immunogenicity or cause 
inactivation. Therefore, to increase the stability of these proteins, an understanding of their 
degradation is necessary. The research covered in this dissertation focused on two major 
degradation mechanisms for an IgG monoclonal antibody (mAb): chemical and physical 
degradation by photo irradiation. First, this dissertation explored the effects of certain 
pharmaceutical excipients on the extent and site-specificity of epimerization in UV irradiated 
mAb formulations. Amino acid analysis of UV irradiated mAb revealed formation of D-Ala, D-
Glu, and D-Val in mAb formulations. Secondly, the underlying mechanism behind the increased 
aggregation propensity of a photo irradiated IgG1 mAb was investigated using hydrogen 
deuterium exchange mass spectrometry and biophysical characterization. Specific correlations 
were established between changes in dynamics of distinct segments in the CH2 domain of the 
IgG1 mAb and decreased thermal stability as well as increase in aggregation propensity of the 
IgG1 mAb on light exposure.  
iv  
This dissertation also describes development of a rapid screening methodology to identify 
protein oxidation by monitoring Tyr and Phe oxidation using fluorogenic derivatization. The 
Fluorogenic derivatization technique was adapted to a 96-well plate, in which several protein 
formulations can be screened in a short time. In addition, this dissertation also outlines the 
capability of an extreme ultra pressure liquid chromatography system in investigating complex 
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1.1 Therapeutic proteins 
In the last 30 years, proteins have emerged as a major class of pharmaceuticals with 
approximately 250 products in the market which are primarily used as therapeutics with a limited 
number as diagnostics.1,2 Protein therapeutics have multiple advantages over small-molecule 
drugs. First, proteins are highly specific in their mode of action, hence less likely to cause side 
effects. Second, proteins are often well tolerated because the body inherently manufactures most 
of the current protein therapeutics. Third, as proteins are distinctive in configuration and 
operation, pharmaceutical companies are capable of obtaining comprehensive patent protection 
for protein therapeutics. The final advantage makes proteins economically appealing compared 
to small-molecule drugs.1-5 
Protein therapeutics can be classified based on their function and therapeutic activity as drugs 
that: 1) substitute a deficient or abnormal protein, 2) enrich an existing pathway, 3) block a 
molecule or organism, 4) provide a unique function or activity, or 5) deliver a cytotoxic drug as a 
payload.2 In addition, protein therapeutics can be grouped into different molecular types that 
include: anticoagulants, blood factors, enzymes, engineered protein scaffolds, thrombolytics, Fc 
fusion proteins, hormones, interferons, interleukins, growth factors, and antibody-based drugs.6,7  
1.2 Rapid growth of monoclonal antibody market 
In the last six years, the U.S Food and Drug Administration (FDA) and the Center for Biologics 
Evaluation and Review (CBER) combined have approved 62 therapeutic proteins, of which 11% 
were enzyme replacement approvals, 19% were coagulation factors, 22% comprised fusion 
proteins, hormones, growth factors, and plasma proteins, and the remaining 48% approvals were 




Monoclonal antibody (mAb) drugs are the fastest and largest growing class of protein 
therapeutics. At the current approval rate of four new products per year, approximately 70 mAb 
products will be on the market by the year 2020, with combined worldwide sales estimated to 
reach $125 billion.9  
The increased interest in antibody drug development is because these products are receptive to 
cost-effective platform-based approaches and predominantly well-tolerated and highly specific.9-
12 The chances of the unexpected safety issues during human clinical trials of mAb products are 
relatively small compared to other therapeutic products. Consequently, for many novel disease 
targets, mAb products are frequently the first line of products advancing to clinical 
development.9 As the patents of many high-profile blockbuster mAb products is expiring, there 
is growing interest in the development of biosimilars, which further could increase the influx of 
mAb products into the market.9-13  
1.3 Antibody structure and instability 
Antibodies are roughly Y-shaped glycoproteins belonging to the immunoglobulin (Ig) family 
which are secreted by B-cells to spot and neutralize antigens or nonnative organisms. Antibodies 
are composed of two identical heavy chains (H, ca. 50 kDa), and two identical light chains (L, 
ca. 25 kDa) with a total molecular weight approximately at 150 kDa.13-15 Antibodies are grouped 
into separate isotypes based on the type of heavy chain they contain. Therapeutic mAbs are 
generally of the γ-immunoglobulin G (IgG) isotype. The amino-terminal variable (V) domains of 
the heavy and light chain (VH and VL, respectively) combine to form an antigen binding domain 
(Fab), while the constant domains (C) form the fragment crystallizable (Fc) domain which is 




inter-chain disulfide bonds. Most IgGs have four inter-chain disulfide bonds: two connecting the 
two heavy chains to light chains and the other two connecting heavy chains at the hinge region. 
Each IgG molecule contains a total of 12 intra-chain disulfide bonds; each disulfide bond is 
associated with an individual domain.14, 16 Like other proteins, antibodies are susceptible to a 
variety of physical and chemical degradation pathways.14, 17, 18  
In general, degradation pathways can be categorized into two major groups: chemical and 
physical degrdation.17,18 Chemical degradation involves the formation of new covalent bonds or 
the breakage of existing covalent bonds, yielding new chemical species,18-22 whereas physical 
degradation refers to changes in the higher order structure (secondary, tertiary, and quaternary 
structures) of the protein, aggregation, precipitation and particle formation.14,18 However, 
chemical degradation can lead to physical degradation and vice versa. Oxidation, deamidation, 
racemization, proteolysis, hydrolysis, β-elimination, disulfide exchange are some of the major 
forms of chemical degradation reported for therapeutic proteins.17,18 Physical degradation 
includes denaturation, aggregation, precipitation and surface absorption.17 These instabilities can 
lead to loss of activity and, in some cases, can cause unwanted immunogenic responses.22,23 Both 
physical and chemical instability can be initiated by multiple factors, such as reactive oxygen 
species (ROS), temperature, shaking, pH, light exposure, etc.18,19,22,24 
1.4 Sources of light exposure in biopharmaceutical industry 
The protein molecules are normally processed under ambient light conditions provided by 
fluorescent, LED and/or metal halide lamps.25 They are exposed to light during various stages of 
their developmental process.24-26 Proteins purified using chromatographic analysis are often 




proteins.24 Light exposure can also occur during the production process.25 For example, 
Mallaney et al. have identified an increase in charge variants during small-scale production of 
mAbs in 2 L bioreactors.25 As the bioreactors were made of clear transparent glass the ambient 
light in the laboratory induced photodegradation in mAb leading to formation of various acidic 
variants. Other potential sources of light exposure occur during fill and finish processes, visual 
inspections, packaging, storage or during drug administration to the patients, e.g. using clear IV 
bags.24,26 The photosensitivity of a protein could be enhanced through the accumulation of 
oxidation products of Trp such as N-Formylkynurenine (λ max = 318 nm), which can function as a 
photosensitizer.24-26 To guarantee that ambient light exposure under good management practice 
(GMP) settings does not alter protein pharmaceuticals to unacceptable levels, regulatory agencies 
have introduced photostability testing.25,26 Photostability testing has become an integral part of 
stress testing for a drug molecule during its submission to the FDA under The International 
Conference on Harmonization (ICH) guideline.27 As indicated in the ICH Q1B guidelines, 
photostability testing under ICH conditions is usually carried out using no less than 1.2 x 106 
lux-hours of visible light and no less than 200 W h/m2 of UV light.26,27 
1.5 Mechanisms of photodegradation in proteins  
Photodegradation can result in altered physical 28 (e.g. conformational changes) and chemical 29-
31 (e.g. oxidation) protein properties, aggregation,28,31 loss of bioactivity30, fragmentation,31 and 
increase in immunogenic potential of the light exposed protein sample.32  
As shown in Figure 1, the indole side-chain of tryptophan (Trp) is the strongest chromophore 
with an absorption maximum at λmax = 280 nm, where the absorbance band extends in to the 




location of the residue in the three-dimensional structure of proteins (solvent exposure).33-35 
Previously, Pigault et al.33 have studied the photo degradation in four different proteins, each 
with single Trp residues with different solvent accessibility. The degree of Trp photodegradation 
was dependent on solvent exposure indicating the effect of Trp location on its light absorption 
ability.33 Additionally, Rao et al.34 have studied the photodegradation of Trp in native and 
random coil forms of melittin and β-lactoglobulin. The results from this study further confirmed 
the effect of protein conformation on the light absorption of Trp.34 Tyrosine (Tyr) absorbs light 
at a much lower intensity when compared to Trp, with its absorption maximum at λmax = 275 nm, 
however there is minimal or no absorbance beyond λ = 290 nm.24 Both phenylalanine (Phe) and 
the disulfide bond absorb light to a similar extent with absorption maxima at 260 nm and 254 
nm, respectively.24,36,37 Absorption spectrum of the disulfide bond is determined by its molecular 
geometry.36 As a result of repulsion between 3pπ orbitals of the sulfur atom, the disulfide bond 
has a dihedral angle of 90o (for C-S-S-C bond) in the unstrained conditions.36,37 Absorption 
spectra of disulfide bond is dependent upon the specific value of the dihedral angle. Large 
alterations from 90o result in absorption at longer wavelengths and a significant decrease in 
absorption.37       
1.5.1 Photo-oxidation  
Photo-induced damage to proteins can occur through two major pathways. The type I pathway 
involves absorption of light (predominately UVB light, λ = 280-320 nm) by specific amino acid 
residues (Trp, Tyr, Phe), cysteine (Cys) and disulfide bonds resulting in excitation of electron to 
higher energy singlet states. The excitation to higher energy state is followed by one of a number 
of processes such as, relaxation to the ground state, formation of a triplet state, reaction with 




(e-aq) and a radical cation.
24,38,39 The Type II pathway involves energy transfer from the triplet 
excited state to ground state triplet oxygen (3O2), forming singlet oxygen (
1O2) which can react 
with other amino acids in the protein.38,39 The amino acids Trp, Tyr, Phe, His, Cys and 
methionine (Met) have been shown to be predominantly susceptible to photo-oxidation. 
The formation of photo-oxidation products is not without consequences for proteins. Photo-
oxidation of proteins can result in an increased extent or susceptibility to unfolding,40 
aggregation,41-45 and fragmentation.45 Photo-induced aggregation (formation of dimers and 
higher molecular weight species) is a well-documented consequence of protein photo-
oxidation.38-45 Aggregates can arise through radical termination reactions, such as reaction of 
Tyr-derived phenoxyl radicals to give di-tyrosine 41,42 or through addition reaction of carbonyl 
groups of the His oxidation products with nucleophilic Lys, Arg and Cys side chains yielding 
covalent cross-links.43,44         
1.5.2 Photodegradation of disulfide bonds 
Chemical degradation of disulfide bonds under neutral or basic conditions can proceed through 
three major pathways: 1) direct attack of sulfur atom by the hydroxyl anion resulting in breakage 
of the disulfide bond, forming sulfenic acid/thiolate anion; 2) the α-elimination caused by the 
hydroxyl ion attacking the β-proton of the Cys residue to yield thiolate/thioaldehyde moieties, 3) 
a β-elimination by abstraction of acidic α-proton of the Cys residue by hydroxyl anion yielding 
dehydroalanine/persulfide.46 But, upon light exposure (UVC, λ = 254 nm) the disulfide bond can 
undergo homolytic dissociation, yielding a pair of thiyl radicals (CysS•) (Fig.2). During 
photoionization of protein, Trp (or Tyr) residues generates electrons, which can reduce nearby 




disproportionation yielding a thiol and thioaldehyde, or participate in reversible hydrogen atom 
transfer reactions with C-H bonds of adjacent amino acids, leading to the formation of carbon 
centered radicals (C•).47-50 The reversible hydrogen atom transfer can be followed by covalent 
deuterium incorporation of deuterium when photolysis of disulfide bonds is achieved in 
deuterium oxide (D2O).
47,49 When such intramolecular hydrogen atom transfer occurs between 
CysS• and C-H of a chiral carbon, the resulting C• exhibits two prochiral faces, where the 
subsequent reversible hydrogen atom transfer yielding either L or D amino acids.52  
1.6 Overview of various novel photodegradation products identified in 
therapeutic proteins 
In recent years, the biopharmaceutical industry has become more aware of the marked sensitivity 
of therapeutic proteins to light. The effects of light exposure vary from protein to protein and are 
dependent upon various formulation factors.43,30 The aim of this section is to provide a brief 
overview on novel photodegradation products identified in therapeutic proteins upon light 
exposure (predominantly UV light). 
Previously, Haywood et al.53 have identified the photolytic cleavage of the Trp side chain (indole 
group) and formation of glycine hydroperoxide (GlyOOH) in the place of Trp on exposure of 
IgG1 to light with λ =  254 nm or λ > 295 nm. This photo-induced lysis proceeds via an 
intermediary radical cation (TrpNH+•) and leads to the formation of C•. This C• likely adds 
oxygen followed by reaction with H donor yielding GlyOOH.  
In another study, Bane et al.45 have identified the formation of a triply oxidized His residue, a 
second doubly oxidized His residue, and Trp side chain cleavage in an IgG1 molecule following 




initiates the oxidation of His leading to formation of endo-peroxide intermediates on the 
imidazole ring. The resulting endo-peroxides lead to the formation of hydroxylated imidazolones 
which were eventually converted into triply oxidized His product through hydrolysis or oxidation 
of hydroxyl imidazolone ring.45 The endo-peroxides formed resultant of light exposure, can also 
be involved in formation of histidine (His-His) cross-links as reported by Liu et al.43 The endo-
peroxides formed are converted to the 2-oxo-histidine and His+32 intermediates, the latter is 
subjected to nucleophilic attack by the unmodified His and finally elimination of H2O to form a 
His-His crosslinks.43  
Disulfide bonds are sensitive to light-induced degradation, where recent studies by Mozziconacci 
et al. with model peptides (containing disulfide bonds),50 oxytocin,54 insulin,55 and IgG1 mAb56 
have indicated the formation of novel photoproducts such as dithiohemiacetals, thioethers, vinyl 
thioethers, D-amino acids, and the conversion of cysteine to alanine and dehydroalanine.48-51,54-57   
1.7 Potential implications of chemical degradation on immunogenicity of 
protein therapeutics 
The potential cause for immunogenicity of protein therapeutics has proven to be difficult to 
predict so far, with many biologics inducing unwanted immune responses.58 These immune 
responses are directed towards the therapeutic resulting in reduced efficacy, anaphylaxis and at 
times life threatening autoimmunity. Development of high affinity anti-therapeutic antibodies is 
the most probable effect of administering an immunogenic therapeutic.58-60 Direct clinical 
evidence of the immunogenicity of chemical degradation products of therapeutic proteins could 
not found.60 However, Chan et al.61 have raised cytotoxic T lymphocytes (CTLs) that identified 




peptides but were less cross-reactive at high concentrations with unmodified parent peptide. 
Similarly, CTLs raised against the unmodified parent peptide did not identify the succinimide 
derivative, implying deamidation or isomerization can lead to autoimmune recognition.61 
Previously, Rasheed et al.62 have demonstrated that human serum albumin (HSA) oxidized 
through ROS was a potent immunogen in rabbits inducing high-titer antibodies, while titer 
against the unmodified HAS was low. The IgG antibodies were specific to HAS oxidized 
through ROS, suggesting generation of neoepitopes by oxidation.62 There are many factors that 
may be involved in the immunogenicity of a biotherapeutic, and these factors can be classified 
into two groups: 1) Patient and treatment-related factors and 2) Product-related factors. Genetics, 
disease state, dose, frequency and route of administration are grouped under patient and 
treatment related factors, whereas contaminants, impurities, chemical and physical degradants 
are grouped under product-related factors.60 Previously, the immunogenicity of protein 
therapeutics has been largely associated with the formation of protein aggregates,63-65 but recent 
studies propose that chemical degradation may also play an important role.66-69 This can be 
explained in different ways: the resultant chemical modifications can induce protein aggregation 
(through covalent cross-links) and formation of neo-epitopes.69 For example, Hermeling et al.66 
showed that recombinant human interferon alpha 2-b (IFNα2b) forms highly immunogenic 
aggregates upon oxidation via Cu+2/ascorbate system. To explain the immunogenic nature of 
these protein aggregates, Torosantucci et al.68 mapped the modifications in oxidized and 
immunogenic aggregates of IFNβ1a. On analysis, several oxidative modifications and covalent 






1.8 Overview of this dissertation 
Physical and chemical instability of proteins due to trace metals, hydroperoxides, and light-
exposure are frequently encountered during production, purification, storage, drug administration 
etc. As described in the introduction, the repercussions of physical and chemical instability, 
specifically oxidation and aggregation can include decreased efficacy and increased 
immunogenicity. To better comprehend the consequences of chemical degradation of protein, the 
extent and nature of chemical degradation products should be characterized thoroughly. 
Understanding the underlying degradation mechanism would provide valuable insights to better 
stabilize and/or design protein pharmaceuticals. 
1.8.1 Dissertation outline 
Chapter 2 discusses development of an efficient and rapid method to monitor the oxidative 
degradation of protein pharmaceuticals:  probing tyrosine oxidation with fluorogenic 
derivatization  
Chapter 3 investigates the effect of various excipients on the extent of epimerization in UV light 
exposed mAb formulation. 
Chapter 4 aims to understand the correlation between photo-degradation and aggregation 
propensity of an UVA light-exposed IgG1 mAb using hydrogen deuterium exchange mass 
spectrometry, biophysical techniques and structural modeling. 
Chapter 5 exploring photo-degradation of rat growth hormone with extreme ultra-pressure 




Chapter 6 summarizes our findings and conclusions of this dissertation and suggestions for 
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Figure 1. Absorption spectra of Trp, Phe, Tyr and CysSSCys (disulfide bond). The picture is 






































Chapter.2 An efficient and rapid method to monitor the oxidative degradation 











Protein pharmaceuticals represent a fast growing class of therapeutics. Since the development of 
the first recombinant protein pharmaceuticals in 1982, more than 170 biotherapeutic products 
have been introduced to treat various diseases such as cancer, autoimmune diseases, allergy, 
infectious diseases, inflammation and various genetic disorders.1-3 The global market for protein 
therapeutics is estimated to be worth $168 billion by 2017.3 Much of the success of protein 
therapeutics is attributed to the influx of a large number of monoclonal antibodies into the 
pharmaceutical market.4  
One of the most demanding tasks in the development of biotherapeutics is to maintain physical 
and chemical stability.3 Protein unfolding, aggregation, surface adsorption and precipitation are 
major forms of physical instabilities encountered by protein therapeutics.3-6 Chemical 
modifications involve covalent changes of chemical bonds, which ultimately lead to the 
formation of new chemical structures. Deamidation and oxidation are among the major chemical 
modification pathways of protein pharmaceuticals.2, 3  
Methionine (Met), cysteine (Cys), tryptophan (Trp), tyrosine (Tyr), phenylalanine (Phe) and 
histidine (His) are significantly more sensitive to a series of oxidation pathways, due to the high 
reactivity of sulfur and aromatic rings towards various reactive oxygen species. 3, 8 Frequently, 
the chemical modifications of these amino acid residues result in structural and biologic 
consequences. For example, the formation of methionine sulfoxide (MetSO) in human IgG1 can 
impact its serum half-life 9, conformational stability 5, and the binding affinity to protein A and 
protein G columns used for purification.10 Likewise, the oxidation of the other amino acids can 




single Trp residue is responsible for the loss of binding and biological activity upon (UV) light 
irradiation in MEDI-493, a monoclonal antibody (mAb) against respiratory syntical virus (RSV). 
11  
 Peptide bond flexibility, protein conformation and surface accessibility of amino acids affect the 
oxidation rates of amino acid residues.8 Buffers, excipients, metal ions, light and temperature are 
also factors, which impact the oxidation pathways of proteins.3,5,8 Autoxidation of polysorbates 
results in the formation of hydroperoxides which can oxidize proteins.12  Polysorbates are the 
most common excipients used in protein formulations to prevent protein aggregation and protein 
surface adsorption.12,13 Trace amounts of metals can be accidentally introduced into protein 
therapeutics during manufacturing and formulation through leaching from metal containers and 
excipients respectively.14 These trace amounts of metal ions can induce metal-catalyzed 
oxidation.15-17  
The oxidation of therapeutic proteins is monitored via a wide array of sensitive analytical 
techniques, including peptide mapping and mass spectrometry.4,18-21 While offering high 
resolution and information on product identity, these techniques are time-consuming. 
The aim of this study is to implement a fluorogenic derivatization method of oxidized Tyr and 
Phe amino acids as an orthogonal technique for the rapid screening of protein oxidation, and to 
evaluate whether a quantitative correlation exists between the oxidation of Tyr/Phe and Met for a 
given protein and specific oxidation conditions. The oxidation of Tyr and Phe generates aromatic 
vicinal diols such as 3, 4 dihydroxyphenylalanine (DOPA)16 which can be derivatized with 
benzylamine derivatives.22 Tryptophan oxidation yields several oxidation products, among them 
5-hydroxy tryptophan (5-HTP), which can also be derivatized benzylamine derivatives.23 DOPA 




benzoxazole (Scheme 1; λem = 490nm, λex = 360nm).
22,23 This method was initially developed to 
monitor oxidized proteins derived from tissue,22,23 but is here applied to the screening of protein 
pharmaceuticals.  To demonstrate that this fluorogenic method can be used as a high-throughput 
assay to screen for the stability of proteins, we evaluated this method with four proteins (bovine 
serum albumin (BSA), human growth hormone (hGH), a monoclonal antibody (IgG1) and 
insulin) exposed to oxidation via peroxyl radicals and metal-catalyzed reactions, respectively. 
Peroxyl radicals (ROO•) were generated through the thermal decomposition of 2,2’-azobis (2-
methylpropionamidine) dihydrochloride (AAPH) 25 (Scheme 2), a process that mimics the 
oxidation of proteins by peroxyl radicals generated from polysorbates.24-26 Metal-catalyzed 
oxidation was initiated through the exposure of proteins to Cu (II)/L-ascorbic acid, or Fe 
(II)/H2O2  These conditions were selected to simulate the effect of trace amounts of metals 
inadvertently introduced into protein formulations during production and storage.27,17 The 
oxidized proteins were reacted with ABS and subsequently placed on a UV-transilluminator 
(Fotodyne Inc., Hartland, WI, USA) to visualize the fluorescent products. For quantitative 
screening, the samples were prepared in a 96 well plate in order to allow simultaneous 
comparison of all proteins and their different responses to different oxidative stresses. 
Representatively for hGH we also quantified MetSO by mass spectrometry, and we related the 
mass spectrometry quantification of MetSO to the ABS derived fluorescence. For this, 
representative ABS fluorescence charts were built by integrating MetSO (quantified by mass 
spectrometry) and ABS fluorescence (measured by fluorescence spectroscopy) to serve as a tool 






2.2 Experimental methods 
2.2.1 Materials 
IgG1 (14 mg/ml) and hGH were provided by Genentech, Inc. (San Francisco, CA. Recombinant 
insulin containing 0.4% (w/w) zinc was purchased from Roche Applied Science (Indianapolis, 
IN). BSA, AAPH, monobasic and dibasic sodium hydrogen phosphate (Na2HPO4 and NaH2PO4), 
ethylenediaminetetraacetic acid (EDTA), L-ascorbic acid , copper dichloride (CuCl2), sodium 
chloride (NaCl), iron (II) sulphate (FeSO4), guanidine hydrochloride, potassium ferricyanide 
K3Fe(CN)6,  iodoacetamide (IAA) , ammonium acetate (NH4C2H3O2), ammonium bicarbonate 
(NH4HCO3), dithiotheritol (DTT), bis (2-mercaptoehtyl) sulphone (BMS)   and hydrogen 
peroxide (H2O2) were purchased form Sigma Aldrich (St. Louis, MO, USA). Trypsin/Lys-C, 
mass spectrometry grade, was purchased from Promega Corporation (Madison, WI, USA). SDS-
PAGE running buffer (100mM Tris, 1.92M glycine and 0.1% (w/v) SDS at pH 8.25) and 
Precision plus Protein dual color standards were purchased from Bio-Rad (Hercules, CA, USA). 
Millipore Q water (milliQ water) was used for the preparation of all the solutions. Optimal water 
and acetonitrile (ACN), containing 0.1% (v/v) formic acid were purchased from Fisher Scientific 
(Waltham, MA). Amicon ultra-0.5 centrifugal filter devices equipped with a 10kDa cut off 
membrane were purchased from Millipore Inc., (Bedford, MA, USA).  4-Aminomethyl-
benzylsulfonic acid (ABS) was synthesized according to published protocol 22.  
2.2.2 AAPH oxidation 
The model proteins (BSA, hGH, IgG1 and insulin) were dissolved at 1 mg/ml in 20 mM sodium 
phosphate buffer at pH 7.2.  The reaction mixtures were prepared by mixing 200 µL of the model 
protein stock solution (1 mg/ml) with a series of concentrations of AAPH, and then incubated at 




Based on the rate of radical generation at 37 oC, 1.36 x 10-6 [AAPH] Ms-1 , 25 a 3 hour incubation 
with 16 mM AAPH generates a total of 2.35 x 10-4 M initial peroxyl radicals. With a 
concentration of hGH (1 mg/ml) at 4.5 x 10-5 M, the maximal ratio of [ROO•] / [hGH] = 5.2. To 
stop the reaction, the oxidized hGH samples were buffer exchanged with 100 mM phosphate 
buffer (pH 9.2) for 12 mins at 14,000 g (4 oC, 3 times) using Amicon ultra- 0.5 centrifugal filters 
equipped with a 10 kD cut-off membrane. In order to test whether we completely stopped the 
reaction we compared two samples (i) AAPH-exposed hGH, which was buffer exchanged, and 
(ii) AAPH-exposed hGH, which was buffer exchanged but incubated for 3 additional hours at 37 
oC. After derivatization with ABS, both samples showed the same fluorescence intensity, 
indicating that all AAPH had been removed by buffer exchange. 
2.2.3 Metal catalyzed oxidation  
2.2.3.1 Cu (II) /L-ascorbate  
Metal catalyzed oxidation of model proteins (1 mg/ml, in 20 mM sodium phosphate buffer, pH 
7.2) by Cu (II)/L-ascorbic acid was performed by mixing model proteins with various 
concentrations of Cu (II) to reach final concentrations ranging from 5 µM to 20 µM. To allow 
binding of Cu (II) to the proteins, the samples were incubated with Cu (II) for ten minutes prior 
to the addition of L-ascorbic acid.29 After ten mins, 500 µM of L-ascorbic acid was added to each 
sample. The final solution was incubated at 37 oC for 3 hours. The reactions were stopped by the 
addition of 50 µL of 50 mM EDTA. 
2.2.3.2 Fe (II)/H2O2/EDTA  
Separate stock solutions of EDTA (20 mM), Fe (II) (10 mM), and H2O2 (10 mM) were prepared 
in Ar-saturated ammonium acetate buffers (20 mM, pH 7.2). 500 µL of the EDTA solution was 




1 mM. After mixing, the solution was again saturated with Ar. Subsequently 200 µL of the 
model protein stock solution (1 mg/ml, in 20 mM ammonium acetate buffer pH 7.2) was mixed 
with 10 µL of the Fe (II) /EDTA solution, and the oxidation reaction was started by the addition 
of 10 µL of the H2O2 stock solution. The samples were incubated at 37 
oC for 3 hours.  The 
reactions were stopped by the addition 250 µL DTPA (1 mM), and 10 µL of catalase (25 µM).  
2.2.4 Fluorogenic derivatization 
After exposure of the model proteins to AAPH and metal catalyzed oxidation, the oxidized 
proteins were buffer exchanged with 100 mM sodium phosphate buffer (pH 9.2) using Amicon 
ultra-0.5 centrifugal filter devices equipped with a 10 kDa cut-off membrane. The optimal 
conditions for the derivatization of DOPA in oxidized proteins with ABS were as follows: 
oxidized protein samples were mixed with K3Fe(CN)6 at a molar ratio of K3Fe(CN)6: protein = 
30:1 in the presence of 10 mM ABS and followed by  incubation of samples in the dark for 90 
mins. The procedures for analysis of the derivatized samples are described in the next two 
sections.  
2.2.5 Size exclusion chromatography (SEC) 
SEC was performed on a Shimazdu HPLC system equipped with two Shimazdu LC-20AT 
pumps (Shimazdu, Columbia, MD) and coupled both to a photo-diode array detector 
(Prominence RF-20A, Shimazdu, Columbia, MD) and a fluorescence detector (RF-20A, 
Shimazdu, Columbia, MD). The samples (90 µL) were injected onto a TSK-GEL G3000swxl 
column (7.8 mm TD x 30 cm, 5 µm, Tosoh Biosciences, King of Prussia, PA, USA). The mobile 
phase consisted of 200 mM sodium phosphate buffer and 50 mM sodium chloride at pH 7.0, and 




2.2.6 Steady-state fluorescence spectroscopy analysis 
The steady-state fluorescence of protein samples derivatized with ABS was measured with a 
Shimazdu RF-5301PC-spectrofluorophotometer equipped with a 1-cm quartz cuvette. 
Fluorescence measurements at λem= 490 nm (λexc = 360 nm) were acquired both in a 500 µL 1-
cm quartz cuvette (Starna cell, Atascadero, CA 93422) and on a 96 well plate model, 
respectively. The excitation and emission bandwidths were set at 5 nm. 
2.2.7 Reduction and alkylation    
Oxidized and control hGH samples were purified through Amicon ultra-0.5 centrifugal filter 
devices equipped with 10 kDa membranes.  The purified hGH samples were reconstituted in 100 
µL of ammonium bicarbonate buffer (50 mM, pH 7.5). The disulfide bonds were reduced by the 
addition of 50 µL BMS (5 mM stock solution in ACN), followed by incubation at 45 oC for 30 
mins. The reduced cysteine residues were alkylated by the addition of 50 µL of IAA (25 mM in 
NH4HCO3 buffer 50 mM, pH 7.4), followed by incubation for 2 hours at 37 
oC. 
2.2.8 Trypsin/Lys-C digestion 
150 µL of reduced and alkylated hGH (1 mg/ml) were mixed with 700 µL HClO4 (0.5 M). The 
samples were centrifuged at 16,000 g at 4 oC for 20 mins and the resulting pellet washed twice 
with milliQ water. The pellet was reconstituted in 200 µL of NH4HCO3 buffer (50 mM, pH 
8).The protein samples were digested with trypsin/ Lys-C (3 µg) in NH4HCO3 buffer (50 mM, 
pH 8) at 37 oC overnight. The proteolytic digests were purified using Amicon ultra-0.5 
centrifugal devices equipped with 10 kDa membranes to separate undigested protein and 





2.2.9 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis  
After reduction and alkylation of Cys residues, 20 µL solution containing either native or 
oxidized hGH (1 mg/ml), and its control were mixed with 1.1 X reducing sample buffer, which 
consisted of 68.89 mM Tris HCl at pH 7.0, 2.2% w/w SDS, 0.044% w/w bromophenol blue, 
22.22% w/w glycerol, and 111.11 mM DTT. The samples were boiled at 100 oC for 2 mins after 
mixing. An aliquot of 20 µL of each sample was loaded onto a 4-20% polyacrylamide gel from 
Bio-Rad (Hercules, CA, USA). Molecular weight standards and Precision Plus Protein Dual 
Color Standards (Bio-Rad) were also loaded onto the same gel. The gel electrophoresis was run 
at a difference of potential of 200 V for 40 mins using 10-fold diluted running buffer. The 
fluorescence bands that contained protein derivatized with ABS, were visualized through a UV-
transilluminator (λ = 302 nm). 
2.2.10 In-Gel digestion  
The fluorescent bands were excised for in-gel digestion, according to the protocol described by 
Shevchenko et al 30. Briefly, the gel slices were first rinsed twice with 100 mM NH4HCO3 (pH 
7.8) in H2O/ACN (1:1 v/v) and then rinsed with 100% ACN at room temperature. The gel slices 
were dried using a Speedvac from Labconco Corp. (Kansas City, MO, USA). The dried gel 
slices were incubated for one hour at 4 oC in 200 µL of 50 mM acetic acid, containing 5 µg of 
sequencing-grade trypsin/Lys-C. An aliquot of 200 µL of 100 mM NH4HCO3 (pH 7.8) was then 
added to the samples prior to protein digestion. The samples were incubated at 37 oC for 8 hours. 
Upon completion of the digestion, the protein solutions were transferred into new 1.5-mL 
Eppendorf vials. The gel slices were rinsed three times with 100% ACN, and the rinsing 




vials. The samples were concentrated using the Speedvac to reach a final volume of 20 µL for 
LC-MS/MS analysis.30 
2.2.11 Mass spectrometry analysis 
LC-ESI-MS experiments were performed on an Acquity UPLC system (Waters Corporation, 
Milford, MA) coupled to either a Xevo Q-TOF (Waters Corporation, U.K) or a linear ion trap 
quadrupole-Fourier transform (LTQ-FT) mass spectrometer (Thermo-Finnigan, Bremen, 
Germany). 
2.2.11.1 Xevo Q-TOF mass spectrometry analysis 
LC-MS analysis were performed on a Xevo Q-TOF mass spectrometer (Waters Corp.,U.K), 
equipped with a nanoAcquity (Waters Corp.,U.K) chromatograph and a BEH nanocolumn (75 
µm x 150 mm C18, Waters Corp.). Aqueous (A) and organic (B) mobile phases consisted of 
optimal water and formic acid (FA) 99.9%: 0.1%, (v:v), and ACN and FA 99.9%: 0.1%, (v:v). 
Tryptic peptides were eluted within 70 mins by increasing mobile phase B linearly from 3 to 
35% (v:v) within the first 50 mins, and by increasing the amount of B to 95% (v:v) within the 
following 20 mins. The flow rate was 0.3 µl/min. The Xevo Q-TOF was operated in the MSE 
mode with all lenses optimized on the [M + 2H]2+ ion for the [Glu]1 -fibrinopeptide B. The cone 
voltage was 25 V, and Argon was admitted to the collision cell. The spectra were acquired using 
a mass range of 150-2,000 Da. The data were accumulated for 0.5 s per cycle. MS/MS 
measurements were performed by ramping the collision energy from 10V to 40V. 
2.2.11.2 LTQ-FT mass spectrometry analysis  
Experiments were carried out on a linear ion trap quadrupole-Fourier transform (LTQ-FT) ion 




acquisition (DDA) mode. All the lenses were optimized on the [M+H]+ ion from leucine 
enkephalin. Tryptic digests were eluted on a non-porous Presto FF-C18 column (15 cm x 0.5 
mm, 2 µm, Imtakt USA, Portland, USA) at a flow rate of 5 µl/min. The ESI source was operated 
with a spray voltage of 2.8 kV, a tube lens offset of 96 V and a capillary temperature of 200 oC. 
The mobile phases consisted of water, ACN and FA at a ratio of 99.9%:0%:0.1%, (v:v) for 
solvent A and 0%:99.9%:0.1%, (v:v) for solvent B. The raw files from the FT-ICR 
measurements were read by the Xcalibur 2.0 software package (Thermo Scientific, Waltham, 
MA) and analyzed with MassMatrix.30 
2.2.12 Calibration curves 
A calibration curve for mass spectrometry analysis was built by plotting the peak areas of the 
Glu-Fib peptide against a series of known concentrations of the Glu-Fib peptide. Glu-Fib was 
provided as lyophilized powder, to which 0.1% FA in optimal water was added to bring the 
concentration to 100 µM. A dilution series was prepared by addition of 0.1% FA in optimal 
water. Calibration curve built with concentrations ranging from 2-2000 nM (Fig. 1b). The 
calibration curves were built using peptide peak intensity measurements, which involved 
extraction of ion chromatograms from the LC-MS runs of the Glu-Fib peptide followed by 
calculation of peak areas. Calibration curves were built by plotting peak areas of the extracted 
ion chromatograms versus the theoretical concentrations. In the calibration curves, the slopes are 
representative of the sensitivities of the mass spectrometry method used for the analytes. The 
precision of the data was determined by measuring 3 replicates of one sample, which is 
represented by standard deviation. The two calibration curves were built to bracket the limit of 
quantification and the upper limit of linearity. Limit of quantification (LOQ, 5 nM) is the lowest 




describes the highest concentration of analyte above which linearity cannot be established 
between concentration and peak area.31 
2.2.13 The use of a 96 well-microplate to efficiently monitor oxidized proteins 
by ABS derivatization  
To assess the presence of oxidized proteins in a large variety of protein samples we performed 
the fluorogenic derivatization with ABS in a 96 well microplate. BSA (1 mg/ml), IgG1 (1 
mg/ml), insulin (1 mg/ml) and hGH (1 mg/ml) were oxidized with either AAPH, Fe 
(II)/H2O2/EDTA, or Cu(II)/L-ascorbate. After incubation, the samples were buffer exchanged 
with 100 mM sodium phosphate buffer (pH 9). Samples were centrifuged at 14,000 g for 12 mins 
in Amicon 0.5-ultra filters equipped with 10 kD cut-off membranes. After the centrifugation, 
samples were measured for protein concentration and adjusted accordingly before loading the 
samples into the well plate. 200 µL of each sample was transferred to a 96 well microplate. After 
loading the oxidized samples to the microplate, 50 µL of 60 mM ABS stock solution was added 
to the samples at final concentrations of 10 mM ABS, followed by the addition of 50 µL of 3 
mM K3Fe(CN)6 stock solution to a final concentration of 500 µM. After 90 mins, the microplate 
was placed on a UV-Transilluminator (operated at λ = 302 nm) for visualization of the 
fluorescence, and subsequently placed in a spectrofluorometer to read the absolute intensities.  
2.3 Results 
The two objectives of this study were to establish a rapid screening method for Tyr and Phe 
oxidation and to evaluate whether there is a quantitative relationship between the oxidation of 
Tyr/Phe and Met for a given protein (representatively hGH) and a given oxidative stress system 




detection after ABS derivatization of DOPA, while the oxidation of Met to MetSO must be 
monitored by HPLC coupled to either UV or mass spectrometry detection. 
The results section is divided into four sub-sections. First, we will present the results on hGH 
alone, along with the details regarding the derivatization of DOPA by ABS. In the second sub-
section, we will characterize the formation of MetSO in oxidized hGH. The third sub-section will 
focus on the development of ABS fluorescence charts to relate the quantification of MetSO by 
LC-MS to the fluorescence detection of DOPA in oxidized hGH. Finally, the development of a 
high-throughput assay to simultaneously screen for the oxidative degradation of a series of 
model proteins will be described. 
2.3.1 ABS derivatization to monitor the formation of DOPA in oxidized hGH    
After ABS derivatization of hGH oxidized with AAPH, we observed the formation of the 
fluorescent benzoxazole (λem = 490 nm on excitation at λexc = 360 nm) (Fig. 2, blue, a). The 
control (non-oxidized hGH), which underwent the same protocol for ABS derivatization showed 
little fluorescence (Fig. 2, black, b).                                                                                   
The ABS-dependent fluorescence intensity increases with the increase in concentration of AAPH 
(1 mM to 16 mM) used to oxidize hGH, indicating an AAPH-dependent increase of Tyr/Phe 
oxidation (Fig. 3). However, this increase is not linear over the range of AAPH concentration 
suggesting different sensitivity of different Phe/Tyr residues to AAPH derived oxidation. Similar 
observations were made by SEC analysis and fluorescence detection (Fig. 4, Fig. S3). hGH 
degradation induced by AAPH was monitored using SEC coupled to diode array detector (Fig. 





2.3.2 SDS-PAGE analysis of ABS-derivatized oxidized hGH  
After the incubation of hGH with different initial concentrations of AAPH (ranging from 1 mM 
to 16 mM), the protein was derivatized with ABS, followed by reduction and alkylation of 
derivatized hGH. The samples were then fractioned by SDS-PAGE.  
The fluorescence intensity increased from lane 2 to lane 7 (Fig. 5) for both monomers and dimers 
(covalent aggregates) of hGH, which indicates the presence of oxidized Tyr and / or Phe that are 
derivatized with ABS, in both monomer and dimer. In addition, as we progress from lane 2-7, a 
smear of fluorescence starts to appear in the higher molecular weight region indicating the 
formation of higher molecular weight aggregates with oxidized Tyr and / or Phe. These 
observations confirm that the formation of DOPA increases with the increase in the initial 
concentration of AAPH.  
2.3.3 Identification of DOPA and ABS derivatized peptides 
The most intense fluorescent bands (corresponding to monomers) from the SDS–PAGE were 
excised and subjected to in-gel digestion, and the tryptic peptides were extracted and analyzed by 
LC-MS/MS. After oxidation of hGH, MS/MS analysis of the proteolytic peptides indicates 
hydroxylation of Tyr-35 in the tryptic peptide QEFEEAYIPK, where the fragment ions y3, y4, 
b3, and b4 demonstrate an increase of +16 Da of Tyr-35 (Fig. 6). After ABS-tagging of oxidized 
hGH, the LC-MS analysis of the tryptic digest revealed that the mass of the peptide 
QEFEEAYIPK increased by +197 Da, as expected for derivatization of DOPA with ammonia 
and ABS. The MS/MS spectrum confirms the conversion of Tyr 35 into benzoxazole (Fig. 7) and 
the structure is shown in the insert of Fig.7. Indeed, the parent ion with m/z of 1450.39 




QEFEEAYIPK. The series of y1-y4, and b1-b4 fragment ions indicate that the mass increase of 
197 Da is located at Tyr-35. We also detected derivatization of DOPA with two ABS molecules 
(Fig. 8), consistent with the reaction mechanism of ABS derivatization.22,23 This twofold 
derivatized parent ion with m/z 1620.39 corresponds to an increase of +366 Da relative to the 
original tryptic peptide QEFEEAYIPK. This tryptic peptide originally contains also Phe, which 
is an additional potential target for oxidation.14 The series of y5-y8 and b1-b3 fragment ions 
shows no sign of derivatization at the original Phe-32 residue. The increase of +366 Da is located 
between the fragment ions y3 and y4, demonstrating that the addition of two molecules of ABS 
occurred at the original Tyr-35 residue. We observe no significant oxidation of Tyr-103 under 
our reaction conditions. However, this is not surprising as low yields of Tyr-103 oxidation were 
previously observed for much stronger oxidizing conditions, where [ROO•] / [hGH] = 30.28 In 
contrast, under our experimental conditions, [ROO•] / [hGH] = 5.2. 
2.3.4 Identification of MetSO by LC-MS 
hGH is a single chain protein consisting of 191 amino acids residues which contains three Met 
residues Met-14, Met-125, and Met-170 (Table 1). Only Met-14 and Met-125 were oxidized to 
MetSO with significant yields after incubation of hGH with various concentrations of AAPH.28 
After oxidation of hGH, the MS/MS spectrum of the tryptic peptide LFDNAMLR showed that 
Met-14 was oxidized to MetSO. The fragment ions y3 and b6 confirm an increase of +16Da at 
Met-14 (Fig. 9). Our analysis also revealed that Met-125 in the tryptic peptide 
DLEEGIQTLMGR was oxidized to MetSO. The latter was demonstrated by its MS/MS 
spectrum, which indicated through the formation of the y3 and b10 fragment ions that oxidation, 




MetSO in oxidized hGH was quantified as follows: The sum of the ion intensities of the oxidized 
tryptic peptides LFDNA(MetSO)LR and DLEEGIQTL(MetSO)GR was compared to the Glu-Fib 
calibration curve (Fig. 11). To compensate any potential variation of the amount of MetSO to the 
variability of the recovery of the peptides after digestion, the MetSO containing peptides were 
normalized to the intensity of the oxidation resistant peptide SNLELLR. Quantification of 
MetSO was achieved assuming that MetSO containing peptides ionized similarly than the Glu-
Fib peptide during ESI. 
2.3.5 Correlation of DOPA fluorogenic derivatization with MetSO formation 
in oxidized hGH 
The steady-state fluorescence intensities of ABS-derivatized hGH were plotted against the 
amount of MetSO detected by LC-MS (Fig. 12). The plot shows two distinct regions: for 
fluorescence intensities up to ca. 330 au, a ca. 6.6-fold increase in fluorescence (between ca. 50 
and 330 a.u.) is accompanied by a ca. 5-fold increase in MetSO. However, for fluorescence 
intensities between 330 and 600 a.u., a < 2-fold increase in fluorescence intensity is accompanied 
by an almost 3-fold increase in MetSO. The existence of these specific regions can be 
rationalized by different sensitivities of various Tyr and Met residues towards oxidation. 
Nevertheless, these charts containing plots of fluorescence vs. MetSO permitted to predict the 
amount of MetSO without performing an LC-MS analysis. The robustness of this method was 
tested by the incubation of hGH with various AAPH concentrations which were not used to build 
the fluorescence vs. MetSO plots. For example, hGH was oxidized in presence of 7 mM AAPH 
for 3 hours at 37 oC. The oxidized hGH was reacted with ABS and the measured fluorescence 
intensity of 370 au was used to estimate the amount of MetSO to 1.6 nanomoles (± 0.054). This 




independently determined by mass spectrometry. We note, that a fluorescence chart built for one 
specific protein cannot be used to predict the oxidation of another protein, due to differences in 
sequence and, most likely, in the sensitivities of Met and Tyr to oxidation in different proteins. 
Hence, separate fluorescence charts have to be constructed for individual proteins. 
2.3.6 Fluorescence visualization of ABS derivatized protein samples by UV-
transilluminator 
The model proteins (hGH, IgG1, insulin and BSA) were exposed to various oxidation conditions, 
followed by derivatization with ABS and fluorescence visualization on the UV-Transilluminator. 
Experiments were performed in a 96 well plate (one entire column on the microplate was loaded 
with the same protein). Model proteins exposed to AAPH, Cu (II)/L-ascorbate and Fe (II)/H2O2 
were loaded to columns 1-4, 6-9 and 10-12, respectively in the microplate (Fig. 13). The first two 
wells in column 5 (5a and 5b) were loaded with derivatization reagents alone (ABS and 
K3Fe(CN)6) to monitor the background. Rows a and e were always loaded with non-oxidized 
(control) proteins exposed to derivatizing conditions with ABS. Table 2 presents the individual 
conditions for each well. Upon visualization (Fig.13), protein samples that were exposed to 
stronger oxidation conditions always showed stronger fluorescence intensities as compared to 
protein samples exposed to lower levels or no oxidation. There was minimal fluorescence in the 
non-oxidized controls. The ABS derivatized fluorescence intensities of the representative 
samples are presented in the supplementary material (Fig. S5).  
2.4 Discussion 
The length and intricacy of the development process for protein pharmaceuticals require the 




screening products, ranging from early stage36 to late stage formulation development.37 The 
benefits of high-throughput screening rely on a rapid analysis, which permits to collect a 
substantial amount of data to preclude the release of unstable products. In the pharmaceutical 
industry any process, which can fulfill these requirements can help in introducing protein 
pharmaceuticals faster into the market. Another advantage of high-throughput screening is the 
possibility to analyze a broad variety of samples (e.g. different proteins) at the same time.36,37  
We have developed a quick and sensitive chemical assay to monitor the level of oxidation of 
proteins. Our assay is based on the derivatization of DOPA with ABS, which specifically allows 
for the detection of oxidation products of Phe and Tyr.14,22,23 We adapted our assay to a 96 well 
microplate framework, where four different non-oxidized (control) and oxidized model proteins 
(IgG1, insulin, hGH and BSA) were ABS-derivatized in a single microplate. The latter was 
placed on a UV-Transilluminator to reveal the specific fluorescence of the benzoxazole product, 
which resulted from the reaction between DOPA and ABS. This plate could also be read in a 
high throughput fashion on a fluorescence plate reader. The fluorescence values could be 
correlated to a previously generated interpolation curve like has been made for hGH. 
Model proteins were exposed to increasing amounts of peroxyl radicals (ROO•), which were 
generated by thermolysis of AAPH in air saturated aqueous solution at a rate of 1.36 x 10-6 
[AAPH] Ms-1.38 Our assay correlates the increase of fluorescence intensities, resulting from the 
derivatization of DOPA by ABS, with the exposure of proteins to increasing amount of ROO• 
(Fig 3). Based on a calibration curve generated by Sharov et al.,22 the amount of DOPA 
generated on hGH by exposure to increasing amounts of peroxyl radicals from AAPH was 
estimated to be between 1.02 pico moles (1.1 µmoles per mole of protein) and 6.1 pico moles 




fluorescence intensity between 70 and 600 a.u. on our plate reader. Therefore, under our 
experimental conditions the ratio of Met oxidation over Tyr/Phe oxidation in hGH, was ca. 
767:1.  We also did observe DOPA by LC-MS analysis but its level was below the limit of 
quantification by MS. 
MetSO represents one of the major degradation products in protein therapeutics, which can 
potentially impact protein pharmaceuticals.8,9 In addition, MetSO is frequently monitored as a 
representative oxidation product of protein pharmaceuticals. Typically, MetSO is detected by 
peptide mapping in combination with LC-MS analysis, which does not permit rapid screening of 
multiple formulations. Our fluorogenic assay shows that after exposure of hGH to AAPH, the 
amount of DOPA in oxidized hGH correlates quantitatively with the formation of MetSO which 
was measured by LC-MS. Based on our observations the key to this correlation is likely the 
parallel reaction of ROO• with both Tyr and Met, as outlined in Scheme 3. Upon thermolysis of 
AAPH in air, the formation of carbon-centered radicals yields ROO• (Scheme 2) which oxidize 
tyrosine to tyrosyl radicals (TyrO•, Scheme 3, reaction 1). TyrO• can further react with peroxyl 
radicals to form DOPA (Scheme 3, reaction 2), which can be derivatized with ABS to form the 
fluorescent benzoxazole derivative (Scheme 1). In parallel, ROO• reacts via two-electron 
oxidation with Met yielding MetSO and an alkoxyl radical 39 (RO•, Scheme 3, reaction 3). RO• 
can oxidize Tyr to yield DOPA via formation of TyrO• (Scheme 3, reactions 4 and 5). Because 
DOPA and MetSO are formed simultaneously and originate from the same oxidants (i.e. RO•, 
ROO•), the identification and characterization of one of these oxidation products allows for 
predicting the formation of the others. We note that analogous linear correlations between DOPA 




may vary depending on the preference of the specific oxidants for Tyr and Met, respectively. The 
only exception will be peroxides in the absence of metals, where peroxides would react nearly 
exclusively with Met to generate MetSO (i.e., in the absence of metals, no Fenton-type reaction 
is expected). However, as most proteins will show trace of metal contaminants such conditions 
are frequently not met in pharmaceutical formulations.     
2.5 Conclusions 
Our rapid fluorescence based screening allows for the fast comparison of the stability of multiple 
formulations, for example in 96 well plates. Subsequent in depth LC-MS analysis can then be 
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Scheme 1:  Schematic representation of the fluorogenic derivatization of DOPA with ABS.  
 
 
Scheme 2:  Mechanism of thermolysis of AAPH, production and reaction of peroxyl radicals 























           Tryptic peptide 
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   Met-14 
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         979.50 
 
   Met-125 
 
        DLEEGIQTLMGR 
 
         1361.67 
 
  Met-170 
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(a)                                                                (b) 
Figure 1. Calibration curves obtained on Xevo-QTOF, using Glu-Fib standard peptide. (a) Glu-Fib 
concentration: 2 – 160 nM. (b) Glu-Fib concentration: 160-2000 nM. 
 
 
Figure 2. Steady state fluorescence monitored after ABS derivatization of a) hGH oxidized with 2mM 
AAPH at 37oC for 3 hours (blue), b) non-oxidized hGH (black), c) the background fluorescence of the 








Figure 3. Fluorescence (λem max) after ABS derivatization of hGH (1mg/ml), oxidized in the presence of 
different initial concentrations of AAPH ranging from 0 (non-oxidized) to 16 mM, at 37oC for 3 hours   
and monitored by steady-state fluorescence as shown in Fig. 2.  
 
 Figure 4. Size exclusion chromatography (SEC) of ABS tagged oxidized hGH (1mg/ml). Fluorescence 
detection (Ex 360nm-Em 490nm) of a) non-oxidized but ABS-derivatized (black), oxidized hGH 
obtained after incubation of hGH with b) 1 mM AAPH (dark blue), c) 2 mM AAPH (pink), d) 4 mM 




















Figure 5. SDS-PAGE analysis (reducing conditions) and fluorescence visualization of oxidized hGH 
(1mg/ml) after ABS derivatization. Fluorescence was recorded by UV Transilluminator (Lane-1: 
molecular weight standards, Lane-2 hGH non-oxidized (control), Lane-3: hGH oxidized with 1mM 
AAPH, Lane-4: hGH oxidized with 2mM AAPH, Lane-5: hGH oxidized with 4mM AAPH, Lane-6: hGH 
oxidized with 8mM AAPH, Lane-7: hGH oxidized with 16mM AAPH, Lane-8: derivatization reagents, 











Figure 6. Collision-induced dissociation (CID) obtained on an FT-LTQ mass spectrometer of the 
oxidized tryptic peptide QEFEEY (+16 Da) IPK.  
 
Figure 7. Collision-induced dissociation (CID) obtained on an FT-LTQ mass spectrometer of the tryptic 





Figure 8. Collision-induced dissociation (CID) obtained on an FT-LTQ mass spectrometer of the tryptic 
peptide QEFEEY(+366 Da)IPK, generated through oxidation and ABS derivatization of hGH. 
 
Figure 9. Collision-induced dissociation (CID) obtained on an FT-LTQ mass spectrometer of the 






Figure 10. Collision-induced dissociation (CID) obtained on an FT-LTQ mass spectrometer of the 
oxidized tryptic peptide DLEEGIQTLM (+16 Da) GR. The peptide is the result of tryptic digestion of 
oxidized hGH. 
   
Figure 11. LC-MS analysis: Formation and quantification of MetSO during oxidation of hGH by serial 
concentration of AAPH ranging from 0 (non-oxidized) to 16mM on incubation for 3 hours at 37oC. The 





Figure 12. ABS fluorescence chart acquired after plotting fluorescence of ABS tagged DOPA against 
the amount of MetSO detected by LC-MS in hGH oxidized with increasing concentration of AAPH 









    
Figure 13. Fluorescence visualization on a UV-Transilluminator (𝜆 = 302𝑛𝑚). IgG1, hGH, Insulin and 
BSA protein samples were oxidized with respective oxidative stressing systems and derivatized with 
ABS.1a hGH control, 1b-1d hGH oxidized with 1, 4, 8 mM AAPH respectively, 2a IgG1 control, 2b-2d 
IgG1 oxidized with 1, 4, 8 mM AAPH respectively, 3a Insulin control, 3b-3d Insulin oxidized with 1, 4, 
8 mM AAPH respectively, 4a BSA control, 4b-4d BSA oxidized with 1, 4, 8 mM AAPH respectively. 5a 
tagging reagents, 5b 100mM dibasic sodium phosphate buffer. 6a hGH control, 6b-6d hGH oxidized with 
5, 10, 15 µM Cu (II) respectively and 500µM L-Ascorbic acid, 7a IgG1 control, 7b-7d IgG1 oxidized 
with 5, 10, 15 µM Cu (II) respectively and 500µM L-Ascorbic acid, 8a Insulin control, 8b-8d Insulin 
oxidized with 5, 10, 15 µM Cu (II) respectively and 500µM L-Ascorbic acid, 9a BSA control, 9b-9d 
BSA oxidized with 5, 10, 15 µM Cu (II) respectively and 500µM L-Ascorbic acid. 10a hGH control, 10b-
10c hGH oxidized with 10, 20 µM Fe (II) + H2O2, 11a IgG1 control, 11b-11c IgG1 oxidized with 10, 20 
µM Fe (II) + H2O2, 12a Insulin control, 12b-12c Insulin oxidized with 10, 20 µM Fe (II) + H2O2. 







Fig. S1 Fluorescence after ABS derivatization of hGH (1mg/ml), oxidized in the presence of different 
initial concentrations of Cu (II) ranging from 0 (non-oxidized) to 40µM, at 37oC for 3 hours   and 
monitored by steady-state fluorescence as shown in Fig. 2. Each data point represents the mean of four 
different experiments ± standard deviation. 
 
Fig. S2 LC-MS analysis: Formation and quantification of MetSO during oxidation of hGH by serial 
concentration of Cu (II) ranging from 0 (non-oxidized) to 40µM on incubation for 3 hours at 37oC. Each 





Fig. S3 Quantification of fluorescent peak area of hGH (1mg/ml), oxidized in the presence of different 
initial concentrations of AAPH ranging from 0 (non-oxidized) to 16 mM, at 37oC for 3 hours   and 
monitored by SEC analysis and fluorescence detection as shown in Fig. 4. 
 
 
Fig. S4 SEC-UV chromatograms (λ = 280nm) to monitor hGH degradation on incubation with AAPH. a) 
non-oxidized but ABS-derivatized (black), oxidized hGH obtained after incubation of hGH with b) 1 mM 
AAPH (dark blue), c) 2 mM AAPH (pink), d) 4 mM AAPH (brown), e) 8 mM (green) and with f) 16 mM 





Fig. S5 Fluorescence intensity readings of respective protein samples, measured using 
spectrofluorophotometer (measurements of well plate in Fig. 13) . IgG1, hGH, Insulin and BSA protein 
samples were oxidized with respective oxidative stressing systems and derivatized with ABS.1a hGH 
control, 1b-1d hGH oxidized with 1, 4, 8 mM AAPH respectively, 2a IgG1 control, 2b-2d IgG1 oxidized 
with 1, 4, 8 mM AAPH respectively, 3a Insulin control, 3b-3d Insulin oxidized with 1, 4, 8 mM AAPH 
respectively, 4a BSA control, 4b-4d BSA oxidized with 1, 4, 8 mM AAPH respectively. 5a tagging 
reagents, 5b 100mM dibasic sodium phosphate buffer. 6a hGH control, 6b-6d hGH oxidized with 5, 10, 
15 µM Cu (II) respectively and 500µM L-Ascorbic acid, 7a IgG1 control, 7b-7d IgG1 oxidized with 5, 
10, 15 µM Cu (II) respectively and 500µM L-Ascorbic acid, 8a Insulin control, 8b-8d Insulin oxidized 
with 5, 10, 15 µM Cu (II) respectively and 500µM L-Ascorbic acid, 9a BSA control, 9b-9d BSA 
oxidized with 5, 10, 15 µM Cu (II) respectively and 500µM L-Ascorbic acid. 10a hGH control, 10b-10c 
hGH oxidized with 10, 20 µM Fe (II) + H2O2, 11a IgG1 control, 11b-11c IgG1 oxidized with 10, 20 µM 
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In the last three decades, monoclonal antibodies (mAbs) have made a considerable 
metamorphosis from being scientific tools to one of the leading group of biotherapeutics.1 
Currently, there are approximately 30 mAbs that have been approved for clinical practice in the 
United States and Europe for various disease conditions, with global sales reaching 
approximately $86.7 billion in 2015.2, 3 
All mAbs have an identical fundamental immunoglobulin (Ig) structure composed of two heavy 
(≅ 50 kDa) and two light (≅ 25 kDa) polypeptide chains, connected through disulfide bonds. 
Each heavy chain is comprised of one variable (VH) and three constant (CH1, CH2 and CH3) 
domains, whereas each light chain is composed of one variable (VL) domain and one constant 
(CL) domain. The Ig’s are further classified into five isotypes, referred to as IgA, IgD, IgE, IgG, 
and IgM based on the structure of their constant domains. Presently, the therapeutically most 
widely used isotype is IgG.3, 4 IgGs can be further classified into four subclasses based on the 
pattern of interchain disulfide bonds: IgG1, 2, 3 and 4. Among these four subclasses, IgG1, 2 and 
4 are used as therapeutics, while IgG3 is rarely used because of its low serum half-life.4 
MAbs are susceptible to various kinds of physical and chemical degradation. Aggregation, 
precipitation and surface adsorption are some of the major forms of physical instabilities, 
whereas deamidation, oxidation and fragmentation represent some of the major forms of 
chemical instabilities.5 Both physical and chemical stability of mAbs can be influenced by 
various external factors such as pH, temperature, excipient impurities, light-exposure, etc.5, 6 
Protein therapeutics are subjected to light-exposure during various stages of their developmental 




The peptide backbone, aromatic amino acids (Tyr, Trp and Phe), His and disulfide bonds are the 
primary targets of photodegradation in proteins.7, 8 In recent years, the pharmaceutical industry 
has become more cognizant of the marked sensitivity of biotherapeutics to light exposure. As of 
now, light-exposure of biotherapeutics has been reported to cause aggregation, oxidation, 
fragmentation, covalent cross-linking, discoloration and color formation.8-10 Therefore, intrinsic 
photostability testing of drug molecules has become an essential part of stress testing to 
demonstrate that light exposure does not result in unacceptable changes.11 
IgG1 represents the most predominant subclass of IgG in human serum and has also been the 
preferred choice for the development of mAb therapeutics. One of the fundamental structural 
hallmarks of the IgG1 subclass is the arrangement of disulfide bonds. IgG1 contains a total of 16 
disulfide bonds comprised of four interchain disulfide bonds in the hinge region and twelve 
intrachain disulfide bonds associated with twelve separate domains. These disulfide bonds play 
an important role in maintaining the tertiary and quaternary structure of the protein.12 However, 
these disulfide bonds are prone to photodegradation via direct photolysis and or electron transfer 
from photo-irradiated Trp, generating cysteine thiyl radicals (CysS•). Thiyl radicals are known to 
react via reversible hydrogen transfer reactions with C-H bonds of adjacent amino acids.13 These 
intramolecular hydrogen transfer reactions yield carbon-centered radicals, which eventually may 
result in the formation of protein hydroperoxides (in presence of oxygen),14 aggregates (covalent 
cross-links)8 or protein fragmentation.15 These reversible hydrogen transfer reactions can be 
probed using covalent deuterium incorporation onto particular amino acids when protein photo-
irradiation is performed in D2O.
16-18 Previous studies have identified covalent deuterium 
incorporation due to reversible hydrogen transfer reaction between CysS• and C-H (as shown in 




also result in the epimerization (L to D) of amino acids. Mozziconacci et al. have demonstrated 
the thiyl radical dependent conversion of L-Ala into D-Ala in disulfide linked model peptides 18 
and the selective epimerization of L-Tyr into D-Tyr and L-Val into D-Val in a UV light-exposed 
mAb. 19 
Protein structure can influence the formation of carbon centered radicals in multiple ways. 
Primarily, the accessibility of C-H bond of an amino acid to the protein CysS• generated during 
photolysis can be affected by protein structure and dynamics.20 Secondarily, homolytic bond 
dissociation energies (BDE) of C-H bonds at the C-alpha carbon are influenced by the type of 
protein secondary structure, in which the amino acid is located, where BDHrandom coil < BDHβ-sheet 
< BDHα-helix. 
21
Moreover, excipients have been shown to change surface properties of proteins, 
leading to changes in secondary and tertiary structure.22,23 Some of the widely used excipients 
can be categorized into the following groups, protein stabilizers (polyols, sugars, salts), 
surfactants ( polysorbate 20 and polysorbate 80) and amino acids .23 In this study, we aim to 
understand the effect of various formulation excipients such as arginine (L-Arg), methionine (L-
Met), leucine (L-Leu), sucrose and glucose on the site specificity and extent of epimerization in 
UV light-exposed mAbs using covalent deuterium incorporation and amino acid analysis, 
respectively. We chose these formulations because the physical analysis of the secondary 
structure of an IgG1 has already been documented in such formulations. Previously, Thakkar et 
al.24 have assessed the conformational stability of IgG1 mAb in presence of L-Arg and sucrose 
excipients; through this study L-Arg was found to be a destabilizer, whereas sucrose was found 
to be a stabilizer of mAb. In the same study, Thakkar et al.24 have postulated that the potential 




structure-rich intermediate structure formation, which potentially stabilizes partially altered 
structures; in contrast, sucrose stabilizes the β-structure-rich intermediary structure. 24  
The formation of D-amino acids could impose local conformational changes in proteins, 
potentially leading to the formation of partially unfolded structures, which can serve as 
precursors for the formation of higher molecular weight structures. Therefore, we performed a 
quantitative analysis of D-amino acid formation in monomer and aggregates of a mAb exposed 
to light. For experimental purposes, we chose light of  = 254 nm and  > 295 nm (max = 305 
nm) as an investigative tool. These conditions are different from those recommended by the 
ICH1QB guidelines, but allowed for controlled and rapid experimental procedures using light of 
a limited wavelength region (instead of the broad wavelength region recommended by the ICH, 
i.e. 320-800 nm, which is less suitable for mechanistic studies). Light-induced mAb aggregates 
were separated from monomers using size exclusion chromatography (SEC), and the extent of 
epimerization was monitored using amino acid analysis.       
3.2 Experimental methods 
3.2.1 Materials 
The mAb (50 mg/ml) was provided by Genentech, Inc. (San Francisco, CA). Monobasic sodium 
hydrogen phosphate (NaH2PO4), dibasic sodium hydrogen phosphate (Na2HPO4), monobasic 
potassium hydrogen phosphate (KH2PO4), dibasic potassium hydrogen phosphate (K2HPO4), 
guanidine hydrochloride, iodoacetamide (IAA), sodium acetate, ammonium bicarbonate, 
dithiothreitol (DTT), bis (2-mercaptoethyl) sulphone (BMS), brij surfactant, N-acetyl-L-cysteine 
(NAC), o-phthaldialdehyde (OPA), L-Arg, L-Met, L-Leu, glucose and trypsin (from porcine 




D) was purchased from Cambridge Isotope Laboratories Inc. Millipore Q water (milliQ water) 
was used for the preparation of all the solutions. Sucrose, methanol, trifluoroacetic acid (TFA), 
optimal water and acetonitrile (ACN), containing 0.1% (v/v) formic acid were purchased from 
Fisher Scientific (Waltham, MA). Amicon ultra-0.5 centrifugal filter devices equipped with a 10 
kDa cut-off membrane were purchased from Millipore Inc (Bedford, MA, USA).   
3.2.2 UV irradiation 
3.2.2.1 Sample preparation 
A stock solution of the mAb was dialyzed against 50 mM sodium phosphate buffer (pH 5.5) at 5 
oC using 10 kDa molecular weight cut-off membranes (Slide-A-Lyzer, Thermo scientific, 
Rockford, IL) for 24 hours. Subsequently, the stock solution was concentrated to 150 mg/mL 
using Amicon ultra-0.5 centrifugal filters devices equipped with a 10 kDa cut-off membranes 
(Millipore, Billerica, MA). The concentrations of mAb stock solutions were measured by UV-
spectroscopy at 280 nm, where Abs 0.1% (=1 g/L) = 1.523 cm-1.25 
3.2.2.2 Preparation of excipient solutions 
Solutions which were prepared in D2O will be referred as deuterated solutions, and the solutions 
prepared in H2O will be referred as non-deuterated solutions. Deuterated or non-deuterated 
excipient solutions were prepared by dissolving L-Arg (10 mg/ml), L-Met (10 mg/ml), L-Leu 
(10 mg/ml), glucose (10 mg/ml), or sucrose (10 mg/ml. pD values are reported after correcting 
pH electrode measurements for the deuterium isotope effects (pD = pH + 0.4).26  The pH and pD 





3.2.2.3 Preparation of mAb samples for UV irradiation 
Aliquots of 100 µL of concentrated mAb (150 mg/mL) were diluted with 500 µL of either H2O 
or D2O containing individual excipients (each excipient at a concentration of 10 mg/mL, pH/pD 
of 5.5, and final protein concentration of 25 mg/mL). Each sample was split into two, of which 
300 µL were UV irradiated and the other 300 µL were used as a control sample. The samples 
were purged with argon (Ar) for 90 mins prior to UV irradiation. The samples were UV 
irradiated for 60 min at λ = 254 in quartz tubes, or λmax = 305 nm in pyrex tubes. For proof of 
concept, we exposed the mAb solutions to λ = 254 nm light as these experimental conditions 
would allow us to rapidly optimize the detection of D-amino acids. The UV light with λmax = 305 
nm corresponds to a spectral distribution of approximately 90% of photons in 280 nm – 320 nm 
wavelength range. Importantly, protein Trp residues show absorption bands which can extend to 
about 320 nm,7,27 such that these conditions would allow us to examine specifically the D-amino 
acid formation induced by Trp photo-ionization. All photo-irradiation experiments were 
performed in a UV-irradiator (Rayonet, The Southern New England Ultraviolet Company, 
Branford, CN) equipped with four UV-lamps (RMR-305 or RMR-254). 
3.2.3 Reduction, alkylation and digestion 
All the samples prepared in either D2O or H2O were exchanged into ammonium bicarbonate 
buffer (NH4HCO3, 50 mM, pH 8) using Amicon ultra-0.5 centrifugal filter devices equipped with 
a 10 kDa cut-off membrane (Millipore, Billerica, MA). After the buffer exchange, for each 
sample a volume of approximately 75 µL was recovered and diluted with 425 µL of NH4HCO3 
buffer and exchanged a second time using an Amicon ultra-0.5 centrifugal filter, as described 




NH4HCO3 buffer. An aliquot of 30 µL of buffer exchanged mAb samples (25 mg/ml) were 
placed in 270 µL of guanidine hydrochloride (6 M, pH 8 in 50 mM NH4HCO3 buffer) and 
incubated at 60 oC in the presence of 5 mM bis-(2-mercaptoethyl) sulfone (BMS) for 30 mins for 
the reduction of disulfide bonds. The reduced cysteines were alkylated at 45 oC with 20 mM 
iodoacetamide (IAA). After one hour of incubation the samples were mixed with 300 µL (1:1 
v/v) of 1M perchloric acid and centrifuged at 14,000 g for 20 mins at 4 oC. The supernatant was 
discarded and the resulting pellet was washed with 50 mM NH4HCO3 buffer for three times by 
slowly adding the buffer without disturbing the pellet. After three washes, the pellet was 
reconstituted in 500 µL of 50 mM NH4HCO3 buffer (pH 8.0) and sonicated for few seconds and 
25 µg of trypsin (from procaine pancreas) was added. The samples were incubated at 37 oC for 2 
hours. After 2 hours, another 25 µg of trypsin (from porcine pancreas) were added and the 
incubation was continued overnight at 37 oC. The digestion was stopped by the addition of 10 µL 
of formic acid and the samples were purified through Amicon ultra-0.5 centrifugal filter devices 
equipped with a 10 kDa cut-off membrane to discard undigested protein and trypsin.  
3.2.4 Size exclusion chromatography (SEC)  
Buffer exchanged mAb samples (both control and irradiated) at 25 mg/mL were diluted to 1 
mg/mL using 200 mM sodium perchlorate buffer and 50 mM sodium chloride (pH 6.0). SEC 
was performed on a Shimazdu HPLC system equipped with two Shimazdu LC-20AT pumps 
(Shimazdu, Columbia, MD), coupled to a Prominence RF-20A photo-diode array detector 
(Shimazdu, Columbia, MD). The samples (90 µL) were injected onto a TSK-GEL SuperSW3000 
column (4.6 mm ID x 30 cm, Tosoh Biosciences, King of Prussia, PA, USA). The mobile phase 
consisted of 200 mM sodium perchlorate buffer and 50 mM sodium chloride at pH 6.0, and was 




were injected for each analytical characterization. Monomer and aggregate fractions were 
collected, using the fraction collector (FRC-10A, Shimazdu, Columbia, MD) connected to the 
system, by making several injections. The collected fractions were pooled and concentrated 
using Amicon Ultra-15 centrifugal devices with 10 kDa cut-off membrane (Millipore, Billerica, 
MA).  
3.2.5 UPLC-MS analysis: Identification of the peptides showing covalent 
deuterium incorporation  
LC-MS analysis was performed on a Xevo Q-TOF mass spectrometer (Waters Corp., Milford, 
MA), equipped with a nanoAcquity (Waters Corp, Milford, MA) set of pumps delivering a 
mixture of mobile phase A consisting of optimal water and formic acid 99.9%: 0.1%, (v:v), and 
mobile phase B, consisting of ACN and formic acid 99.9%: 0.1%, (v:v) at a flow rate of 0.3 
l/min. A volume of 0.5 L of the mAb digest was injected onto reverse-phase CSH 
nanocolumn (75 µm x 150 mm C18, Waters Corp.). Peptides were eluted with linear gradient 
ranging from 3-35% of mobile phase B within 60 mins. 
3.2.6 HPLC UV-Vis analysis: Purification of the peptides showing covalent 
deuterium incorporation 
A volume of 100 L of the digests were injected onto a reverse-phase C18 column (Vydac 
218TP, 250 x 4.6 mm, 5 m) that was connected to a set of pumps (LC-20AT, Shimazdu, 
Columbia, MD), delivering a mixture of mobile phase A (100% H2O, 0.1% TFA) and B (100% 
ACN, 0.1% TFA) at a flow rate of 0.5 mL/min. The C18 column was placed in a column heater 




following gradient program: between 0 and 2 mins the mixture of solvents contained 97% of 
mobile phase A and 3% of mobile phase B. After 2 mins, the mobile phase B was linearly 
increased to 28% within 128 mins. The chromatograms were monitored with a diode array 
detector (SPD-M20A, Shimazdu, Columbia, MD). Proteolytic peptides were collected using a 
fraction collector (FRC-10A, Shimazdu, Columbia, MD), followed by concentrating the fractions 
to a volume of 100 L using a CentriVap concentrator (Labconco, Kansas City, MO).      
3.2.7 Amino acid analysis 
Amino acid analysis consisted of two steps, complete hydrolysis of the substrate (protein or 
peptide) using optimized conditions, which would avoid/ minimize amino acid epimerization 
during hydrolysis, followed by chromatographic analysis and quantification of L- and D-amino 
acids.      
3.2.7.1 Acid hydrolysis of mAb 
The protein concentration of all the fractions (monomer and aggregates) was adjusted to 5 
mg/mL. A custom made glass microplate was used to perform the acid hydrolysis reaction of the 
collected fractions. The glass microplate and 6 N HCl (Pierce, Thermo Scientific, Rockford, IL) 
were placed in a glove bag, which was saturated with nitrogen. A volume of 200 L of 6 N HCl 
(nitrogen saturated) was added to each well. The glass microplate was sealed prior to be removed 
from the glove bag. The sealed glass microplate was transferred to an oven (Precision, 
Winchester, VA) and incubated at 130 oC for 45 mins. The hydrolyzed samples were vacuum 






3.2.7.2 HPLC analysis of L- and D-amino acids 
Volumes of 50 L of hydrolyzed protein solutions prepared in 25 mM aqueous sodium acetate 
(pH 6.5) were transferred to a polystyrene 96 well microplate and placed in an auto-sampler 
(Shimadzu, Columbia, MD ). Three different stock solutions were prepared in order to derivatize 
the amino acids with OPA and NAC. Solution S1 consisted of 9,967 L of K2HPO4 (190 mM, 
pH 9.5) buffer, and 33 L of Brij-35 solution (35% w:v). Solution S2 consisted of 5.5 mg of 
OPA, and 12 mg of NAC in 265 L of methanol and 4,735 L of K2HPO4 (190mM, pH 9.5) 
buffer. Solution S3 consisted of sodium phosphate buffer, NaH2PO4 (200 mM, pH 4.5). 
Solutions S1, S2 and S3 were always placed in the auto-sampler at 5 oC. The solutions were 
mixed together using the auto-sampler to ensure the reproducibility of the derivatization reaction. 
The solutions were mixed as follows: 50 L of each S1, S2 and hydrolyzed protein solution were 
mixed together. During the next one minute, the solution was mixed by soaking and dispensing 
100 L of the solution using the syringe in the auto-sampler. After mixing, the solution was left 
for one more minute at 5 oC in the dark. Then, 150 L of S3 were added to the solution. Again, 
the final solution was mixed for one minute by soaking and dispensing of 100 L of the solution 
using the syringe in the auto-sampler. Then, 50 L of the final solution was injected onto a 
reverse-phase capillary C18 column (Supelcosil LC-18-T, 150 x 4.6 mm, 5 m), which was 
attached to a set of pumps (Shimadzu, Columbia, MD), delivering a mixture of solvents A (25 
mM sodium acetate, pH 6.5 and 5 M sodium azide) and B (100% methanol) at a flow rate of 
0.5 mL/min. The C18 column was always maintained at 35 oC. The mixture of solvents A and B 
was delivered according to the following gradient program: between 0-15 mins the mixture of 




mins. Subsequently, the column was washed for 5 mins with 50% solvent B, and re-equilibrated 
for 40 mins with 100% solvent A prior to the next injection. The chromatograms were recorded 
with a fluorescence detector (RF-20A, Shimadzu, Columbia, MD).   
3.2.8 Incubation with D-amino acid oxidase 
The flavoprotein D-amino acid oxidase (DAAO) is a widely used tool for in vitro enzymatic 
assays for the detection of D-amino acids.29,30 DAAO oxidizes D-amino acids with a strict 
enantioselectivity to produce the corresponding α-keto acids and ammonia.31 This property of 
DAAO was used to confirm the presence of D-amino acids in our protein hydrolysates. 
An enzyme stock solution was prepared by addition of 0.2 mg of DAAO from porcine kidney 
(EC number: 1.4.3.3, Sigma, St. Louis, MO) and 0.5 mg of catalase from bovine liver (EC 
number: 1.11.1.6, Sigma, St. Louis, MO) to 1 mL of Tris buffer (200mM, pH 8.3). The final 
reaction mixture was prepared by addition of 75 µL of enzyme stock solution to 25 µL of protein 
hydrolysate, and incubated at 37 oC for 1 hour. After the incubation, the protein hydrolysate were 
purified using Amicon Ultra-15 centrifugal devices with 10 kDa cut-off membrane (Millipore, 
Billerica, MA) to remove DAAO and catalase from the reaction mixture.      
3.3 Results 
3.3.1 Enrichment of monomer and aggregates using SEC 
The formation of D-amino acids could impose local conformational changes in proteins, 
potentially leading to the formation of partially unfolded structures, which can serve as 




quantitative analysis of D-amino acid formation in monomers and aggregates of a mAb exposed 
to UV light.  
MAb samples in various formulations (pH 5.5) were exposed to UV light for 60 mins. Analytical 
SEC was used to estimate the content of aggregates, monomers and fragments  in both control 
and UV irradiated mAb formulations (Fig. 1, 2, Fig. S1 and S2). The chromatograms showed 
several important differences in UV irradiated samples when compared to their respective 
control samples. The loss of monomer peak (at retention time, tR = 12 min) in UV light-exposed 
samples was accompanied by an increase in earlier eluting peaks (aggregates), eluting with tR ca. 
9 and 10 mins (Fig.1a). The monomer peak also widened upon light exposure. In addition, we 
observed formation of a peak eluting with tR = 14.5 mins (likely fragments). While the control 
samples predominantly contained monomer, and low levels of aggregates (3.7%, ± 0.47), the 
mAb samples exposed to UV light (λ = 254 nm) in presence of either L-Arg, L-Met, glucose, L-
Leu, or sucrose contained 43.6 % (± 4.15), 31.3 % (± 4.99), 35.5 % (± 5.18), 31.6% (± 4.89), and 
41.3% (± 6.9) of aggregates, respectively (Fig. S3a). For all conditions examined, when 
compared to mAb samples exposed to UV light at λ = 254 nm, mAb samples exposed to UV 
light at λmax = 305 nm contained relatively less amount of aggregates and fragment species (Fig. 
S3).     
SEC connected to a fraction collector was used to isolate both monomer and aggregate fractions. 
Approximately 3 injections for each original mAb sample were made for the isolation of 
monomer and aggregate species, followed by pooling and concentration of the samples to obtain 
sufficient protein quantities for future experiments. All the fractions were stored at 4 oC until 





3.3.2 Amino acid analysis of monomers and aggregates 
Monomer and aggregates of interest were subjected to acid hydrolysis, followed by 
derivatization with NAC and OPA. The derivatized L- and D-amino acids were separated by 
reverse-phase liquid chromatography coupled to a fluorescence detector (Fig. S4). 
3.3.2.1 Amino acid analysis of monomer and aggregates resultant of UV irradiation at λmax 
= 305 nm 
Amino acid analysis of control (not UV-irradiated) mAb hydrolysate lead to the identification of 
the following amino acids: (i) L-Asp, (ii) L-Glu, (iii) L-Ser, (iv) L-Thr, (v) L-Arg, (vi) L-Ala, 
(vii) L-Lys, (viii) L-Tyr, (ix) L-Met, (x) L-Val, (xi) L-Phe, (xii) L-Ile, and (xiii) L-Leu. Under 
typical acid hydrolysis conditions Asn and Gln are completely hydrolyzed to Asp and Glu, 
respectively. Trp was completely degraded and Cys cannot be directly determined from the acid-
hydrolyzed samples. Ser and Thr are partially hydrolyzed and usually loss of about 10 and 5 %, 
respectively. Ser and Thr residues can undergo β-elimination during hydrolysis.28   
For example, comparison of amino acid analyses of aggregates (Fig. 3, brown trace) resultant of 
UV light exposure (λmax = 305 nm) of mAb in L-Arg formulation and control mAb monomer 
(Fig. 3, green trace) in L-Arg formulation revealed presence of D-Glu (Fig. 3a), D-Ala (Fig. 3b) 
and D-Val (Fig. 3c) in aggregates resultant of UV light exposure. The absence of D-amino acids 
in control mAb monomer suggest that D-Glu, D-Ala, and D-Val are generated during UV 
irradiation (λmax = 305 nm) of mAb in L-Arg formulation. Amino acid analyses of monomers and 
aggregates, resultant of light-exposure of mAb at λmax = 305 nm in different formulation (L-Arg, 
L-Met, L-Leu, glucose and sucrose) also revealed formation of D-Val, D-Glu and low levels D-




Absence of D-Glu, D-Ala and D-Val in all control mAb samples also suggests that our 
experimental conditions (hydrolysis for 45 minutes) were sufficiently mild to limit D-amino acid 
formation during hydrolysis. On contrary, D-Asp was identified in both control and light-
exposed mAb samples, suggesting that D-Asp is either present in starting material or generated 
during hydrolysis or sample preparation.  
3.3.2.2 Amino acid analysis of monomer and aggregates resultant of UV irradiation at λ = 
254 nm 
Amino acid analyses of monomers and aggregates, resultant of light-exposure of mAb at λ = 254 
nm in different formulation (L-Arg, L-Met, L-Leu, glucose and sucrose) reveals formation of D-
Val, D-Glu and low levels D-Asp in all the samples (Fig. S5). The absence of D-amino acids in 
control mAb monomer suggest that D-Glu and D-Val are generated during UV irradiation (λ = 
254 nm) of mAb in various formulations. 
3.3.3 Quantification of D-amino acids in monomers and aggregates 
After amino acid analysis, the extent of epimerization in monomers and aggregates was 
determined by dividing the peak areas of the respective peaks of D-amino acids by the sum of 
peak areas for both the respective D- and L-amino acids, as shown in the formula below:  
 
% 𝐷 − 𝑎𝑚𝑖𝑛𝑜 𝑎𝑐𝑖𝑑 =  
𝑃𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑜𝑓 𝐷 − 𝑎𝑚𝑖𝑛𝑜 𝑎𝑐𝑖𝑑 𝑝𝑒𝑎𝑘
𝑃𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑜𝑓 𝐷 − 𝑎𝑚𝑖𝑛𝑜 𝑎𝑐𝑖𝑑 𝑝𝑒𝑎𝑘 + 𝑃𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑜𝑓 𝐿 − 𝑎𝑚𝑖𝑛𝑜 𝑎𝑐𝑖𝑑 𝑝𝑒𝑎𝑘
 
 
Quantitative analysis for monomers (Fig. 4a) and aggregates (Fig. 4b), resultant of light-





and low levels D-Asp (around 0.3%) in all the samples, whereas D-Ala was only identified in 
aggregates formed resultant of UV irradiation (λmax = 305 nm) of mAb in L-Arg formulation. For 
example, amino acid analysis of aggregates resultant of light-exposure in the L-Arg-containing 
formulation revealed 13.03 % (± 0.52) of D-Val, 6.69 % (± 0.8) of D-Glu, and 0.21% (± 0.03) of 
D-Ala. 
Quantitative analysis for monomers (Fig. 5a) and aggregates (Fig. 5b), resultant of light-
exposure of mAb at λ = 254 nm in different formulation reveals formation of D-Val and D-Glu, 
while low levels D-Asp (around 0.3%) were present in all the samples. For example, amino acid 
analysis of aggregates resultant of light-exposure in L-Arg formulation revealed 4.47 % (± 0.42) 
of D-Val, and 2.79 % (± 0.18) of D-Glu. 
3.3.4 Identification of D-amino acid containing peptide sequences in UV 
irradiated mAb  
Our strategy to identify D-amino acid-containing sequences in light-exposed mAb is based on 
covalent deuterium incorporation during photo-irradiation of the protein in D2O.
19 Peptides 
incorporating deuterium can be detected by HPLC-MS/MS analysis, their retention time 
recorded, and then peptides eluting with these retention parameters can be fractionated after 
photo-irradiation in H2O. Peptides of interest were fractionated, collected, and subjected to acid 
hydrolysis, followed by derivatization with NAC and OPA for amino acid analysis.  
3.3.4.1 Covalent incorporation of deuterium during UV irradiation of mAb in D2O  
The HPLC-MS analysis of the proteolytic peptides obtained after light-exposure (λmax = 305 nm) 
of mAb formulations in D2O and H2O unveiled five ions with m/z 756.37, 635.30, 356.8, 1030.5, 




8). MS/MS analysis permitted identification of the sequences of the respective peptide ions with 
covalent incorporation of deuterium (Table 1). The ions with m/z 1030.5, 1193.51 and 356.8 
corresponds to heavy chain sequence H51-H59, H51-H60 and H287-H296, respectively. After 
light-exposure of mAb at λmax = 305 nm, only the peptide segments H51-59 and H287-H296 that 
showed covalent incorporation of deuterium were fractionated for amino acid analysis.  
3.3.4.2 Fractionation and amino acid analysis of proteolytic peptides H51-H59 and H287-
H296 
The proteolytic peptides obtained after UV irradiation at λmax = 305 nm of mAb in the L-Arg-
containing formulation were fractionated by HPLC and monitored by UV-detection. The 
collected fractions were reanalyzed by LC-MS analysis to ensure the purity of each fraction (Fig. 
9). The HPLC-MS analysis of fraction 23 revealed peptide segment H287-H296 co-eluting with 
another peptide ion with a mass of m/z 521.3. The peptide ion with m/z 521.3 could not be 
identified by MS/MS analysis, due to poor fragmentation. The amino acid analysis of fraction 23 
(H287-H296 and peptide segment with m/z 521.3) revealed presence of D-Val along with other 
L-amino acids.     
The HPLC-MS analysis of fraction 18 revealed H51-H59 and H319-H324 (proteolytic peptide 
with no covalent incorporation of deuterium) co-eluting with each other. The amino acid analysis 
of peptide segments in fraction 18 (H51-H59 and H319-H324) revealed the presence of D-Ala 
along with other L-amino acids. 
3.3.5 Incubation with DAAO 
Amino acid analysis enabled identification of D-Val, D-Ala and D-Glu in monomers and 




mAb samples, we utilized the ability of DAAO to selectively oxidize D-amino acids to the 
corresponding α-keto acids.29-31 A comparison of the amino acid analyses of the mAb 
hydrolysates prior and subsequent to DAAO treatment revealed the complete disappearance of 
D-Val (Fig. S6), D-Ala (Fig. S7), and D-Glu, consistent with the assignment of these peaks to 
the respective D-amino acids. 
In addition, comparison of the amino acid analyses of the fraction 23 hydrolysate prior and 
subsequent to DAAO treatment revealed the complete disappearance of D-Ala, consistent with 
the assignment of the peak to D-Ala. Incubation of fraction 18 with DAAO also lead to the 
disappearance of the signal for D-Val; however, a residual signal co-eluting with D-Val 
remained due to a contamination of DAAO with an unknown compound, as revealed by control 
experiments with DAAO alone (Fig. S8). This contamination did not affect the analysis of total 
mAb hydrolysate after treatment with DAAO, due to the significantly larger quantity of D-Val 
present after hydrolysis of the entire protein.     
3.4 Discussion 
Due to the chirality of the -carbon (C), all amino acids with the exception of Gly can undergo 
epimerization (conversion of L-amino acid to D-amino acid). Although only L-amino acids are 
used for the synthesis of proteins, D-amino acids have been identified in various proteins from 
human tissue, resultant of post-translational modifications (PTM). For example, D-Asp was 
detected in various proteins from human tissue such as eye lens, skin and bone in elderly people, 
and a high proportion of D-Asp and D-Ser were found in amyloid plaques of Alzheimer’s 
disease. 32-34 Tao et al. have reported on the epimerization of crystallin proteins extracted from 




disordered N-terminal and C-terminal domains.35,36 Even though these modifications are not as 
abundant as the commonly studied PTMs, such as resulting from oxidation and phosphorylation, 
they can affect the higher order structure of a protein, in turn affecting the biological activity of a 
protein. 31 All the examples presented earlier are associated with the identification of D-amino 
acids in biological samples, but recently there has been some evidence showing the formation of 
D-amino acids in therapeutic proteins. Amano et al. have identified specifically the racemization 
of Cys220 in the hinge region of IgG1 upon incubation of the protein at 50 oC and pH 9.37 
Likewise, Zhang et al. have identified the racemization of disulfide Cys residues (HC Cys220; 
LC Cys214) in the hinge region of an IgG1 incubated under basic pH conditions.38 In both of 
these studies reversible -elimination of Cys residues has been presented as the underlying 
reaction mechanism for the base-catalyzed racemization of the hinge region disulfide bond. 37,38 
In another study, Mozziconacci et al. have identified the formation of D-amino acids in specific 
sequences of a UV light-exposed IgG1. 19              
Photo-irradiation of proteins can lead to the formation of thiyl radicals by various mechanisms.39-
41 UV light at λmax = 305 nm is essentially absorbed by aromatic amino acids (Trp, Tyr, Phe).
7,27 
Here, the absorption of light by Trp produces an excited state, which can eventually ionize to 
form a hydrated electron and a radical cation.7 The hydrated electron can reduce a disulfide bond 
to form a disulfide radical anion, which further dissociates into cysteine thiyl radicals (CysS) 
and Cys. Instead, UV light at λ = 254 nm can be directly absorbed by the disulfide bond, leading 
to the homolytic cleavage of the disulfide bonds and generating a pair of CysS radicals.13,16-19,40 
The resultant CysS radicals formed upon light-exposure can participate in intramolecular 
hydrogen atom abstraction from adjacent C-H bonds, leading to the formation of carbon-centered 




bond of the chiral carbon, the resulting carbon atom exhibits two prochiral faces. The reverse 
hydrogen atom transfer can lead to formation of either L- or D- amino acid. 17  
3.4.1 Effect of various excipients on the extent of epimerization in UV 
irradiated mAb formulations  
The formation of D-amino acids could impose local conformational changes in proteins, 
potentially leading to the formation of partially unfolded structures, which can serve as 
precursors for the formation of higher molecular weight structures. Therefore, we performed a 
quantitative analysis of D-amino acid formation in monomer and aggregates of a mAb exposed 
to light.  In this study, a variety of excipients were added to a mAb formulation, such as protein 
stabilizers (sucrose, glucose) and amino acids (L-Arg, L-Met and L-Leu).  
The quantitative analysis for monomers (Fig. 4a) and aggregates (Fig. 4b), resultant of light-
exposure of mAb at λmax = 305 nm in different formulation revealed existence of D-Val, D-Glu 
and low levels D-Asp in all the samples, whereas D-Ala was only identified in aggregates 
formed resultant of UV irradiation (λmax = 305 nm) of mAb in L-Arg formulation. The 
quantitative analysis of monomers (Fig. 5a) and aggregates (Fig. 5b), resultant of light-exposure 
of mAb at λ = 254 nm in different formulation revealed the formation of D-Val and D-Glu, while 
low levels D-Asp were present in all the samples.  
Interestingly, a quantitative analysis revealed higher yields of D-amino acids for both monomers 
and aggregates resultant of UV irradiation (λmax = 305 nm and λ = 254 nm) of mAb in the L-
Arg containing formulation when compared to mAb in other formulations (in L-Met, L-Leu, 
sucrose and glucose). This can be rationalized by an increase in mAb flexibility in the CH1 and 
CH2 domains in the presence of L-Arg, 




formation. In contrast, sugars (sucrose and glucose) are known to increase the compactness and 
rigidity of a protein in aqueous solution. For example, the stabilizing effect of sucrose on protein 
structure was explained by Timasheff et al. by “preferential exclusion” mechanism.43 Based on 
this mechanism, sucrose is preferentially excluded from the protein surface increasing the 
chemical potential of the solution. According to Le Chatlier’s principle, to counteract the 
changes imposed by preferential exclusion a new equilibrium is established to reduce 
thermodynamically unfavorable states, during which proteins adopt to a smaller surface area 
with a more compact and rigid structures.42-44 This rigid nature (less flexibility) of mAb in the 
presence of sugars can minimize the extent of intra-molecular hydrogen transfer reactions thus 
reducing the magnitude of epimerization. 
 3.4.2 Effect of various excipients on the site-specificity of the epimerization in 
UV irradiated mAb formulations 
Intramolecular hydrogen transfer reactions can be monitored using covalent incorporation of 
deuterium when photolysis of disulfide bond happens in presence of D2O. In this study, we have 
identified selective addition of deuterium into five peptides for mAb in L-Arg and L-Met 
formulations, and four peptides for mAb in sucrose, glucose and L-Leu formulations (Table. 1 
and Table 2). These results illustrate that protein CysS radicals generated resultant of photolysis 
of disulfide bonds in mAb abstract hydrogen atoms from specific sequences. The differences in 
deuterium incorporation in mAb in presence of various formulations suggest an influence of 
mAb conformation on protein CysS radical formation and reactivity. Protein conformation can 
influence the formation of carbon-centered radicals by controlling the accessibility of C-H bond 
to the protein CysS radicals formed during light-exposure. However, covalent deuterium 




epimerized, as intramolecular H atom transfer between CysS and C-H bond of a non-chiral atom 
will still exhibit covalent deuterium incorporation, but will not be involved in epimerization. As 
a proof of concept, the amino acid analyses of peptide segments H51-H59 and H287-H296 
(peptide segments that showed covalent incorporation of deuterium) revealed presence of D-Ala 
and D-Val, respectively.  
The peptide segment H51-H59 is present in the complementarity-determining region (CDR), 
thus presence of epimerized amino acids is likely to have an effect on the binding affinity of a 
mAb to the target and, therefore have an effect on its potency.  
3.5 Conclusion     
Our results show that UV light-exposure (λmax = 305 nm and λ = 254 nm) can induce 
epimerization of particular amino acid residues in mAb. As the epimerization of certain amino 
acids could lead to loss of biological activity of IgG, high extra care should be taken to limit the 
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Scheme 1: The intramolecular H atom transfer occurring between the thiyl radical of the cysteine 














   Position 
 
   L-Arg 
 
 
   L-Met 
 
     L-Leu 
 




    H51-H59 
        
 













    H51-H60 
        
 













   H287-H296 
       
 













  H353-H357 
 













  H392-H397 
 













Table 1. List of proteolytic peptides with covalent deuterium incorporation after UV light-
exposure (λmax = 305 nm) of mAb in five (L-Arg, L-Met, L-Leu, sucrose and glucose) different 












Figure 1. SEC analysis of mAb samples exposed to UV (λmax = 305 nm) irradiation for 60 min. 
(a) Overlay of SEC chromatograms of mAb in L-Arg formulation, without light exposure 
(control, black trace) and exposure to UV light for 60 min (red trace). (b) Overlay of SEC 
chromatograms of mAb in L-Met formulation, without light exposure (control, black trace) and 





Figure 2. SEC analysis of mAb samples exposed to UV (λ = 254 nm) irradiation for 60 min. (a) 
Overlay of SEC chromatograms of mAb in L-Arg formulation, without light exposure (control, 
black trace) and exposure to UV light for 60 min (red trace). (b) Overlay of SEC chromatograms 
of mAb in L-Met formulation, without UV irradiation (control, black trace) and with UV 





Figure 3.  Amino acid analysis of aggregates resultant of UV irradiation (λmax = 305 nm) of mAb 
in L-Arg formulation (brown trace) and control mAb in L-Arg formulation (green trace). Amino 
acid standards L-Glu (black trace, a), D-Glu (red trace, a) L-Arg (black trace, b), D-Arg (red 
trace, b), L-Ala (black trace, b), D-Ala (red trace, b), L-Met (black trace, c), D-Met (red trace, c), 
L-Val (black trace, c) and D-Val (red trace, c). The HPLC chromatograms are recorded using a 





Figure 4. Quantitative analysis of D-amino acids identified in (a) monomer, and (b) aggregate 
fractions generated after UV (λmax = 305 nm) irradiation of mAb in L-Arg, L-Met, L-Leu, 




Figure 5. Quantitative analysis of D-amino acids identified in (a) monomer, and (b) aggregate 
fractions generated after UV (λ = 254 nm) irradiation of mAb in L-Arg, L-Met, L-Leu, glucose 







Figure 6. Comparison of the isotopic distributions of the ion with m/z 1030.44 (H51-H59) 
generated after the digestion of control mAb in H2O (a, black) and D2O (a, red), and UV 








Figure 7. Comparison of the isotopic distributions of the ion with m/z 1193.51 (H51-H60) 
generated after the digestion of control mAb in H2O (a, black) and D2O (a, red), and UV 








Figure 8. Comparison of the isotopic distributions of the ion with m/z 356.8 (H287-H296) 
generated after the digestion of control mAb in H2O (a, black) and D2O (a, red), and UV 






Figure 9. HPLC chromatogram, recorded at λ = 280 nm, of a proteolytic digest of a mAb, which 
had been UV-irradiated (λmax = 305 nm) in an L-Arg-containing formulation. Chromatographic 
peaks were collected into individual fractions. Proteolytic peptides with covalent incorporation 
of deuterium were present eluting in fraction 18 and 23. The purity of these fractions was 
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Fig S1: SEC analysis of mAb samples exposed to UV (λmax = 305 nm) light for 60 min. (a) 
Overlay of SEC chromatograms of mAb in (a) leucine formulation, without light exposure 
(control, black trace) and exposure to UV light for 60 min (orange trace), (b) glucose 
formulation, without light exposure (control, black trace) and exposure to UV light for 60 min 
(purple trace), (c) sucrose formulation, without light exposure (control, black trace) and exposure 





Fig S2: SEC analysis of mAb samples exposed to UV (λ = 254 nm) light for 60 min. Overlay of 
SEC chromatograms of mAb in (a) leucine formulation without light exposure (control, black 
trace) and exposure to UV light for 60 min (orange trace), (b) glucose formulation, without light 
exposure (control, black trace) and exposure to UV light for 60 min (purple trace), (c) sucrose 
formulation, without light exposure (control, black trace) and exposure to UV light for 60 min 






Fig S3: SEC analysis of mAb samples in different formulations before (control) and after UV 
light exposure for 60 min. The bar graphs represent the amount of aggregates, monomer and 
fragments of mAb as measured on (a) UV light exposure at λmax = 305 nm and (b) UV light 






 Fig S4.  Amino acid analysis of L and D amino acid standards. The HPLC chromatograms are 














Fig S5.  Amino acid analysis of aggregates resultant of UV irradiation (λmax = 254 nm) of mAb 
in L-Arg formulation (brown trace) and control mAb in L-Arg formulation (green trace). Amino 
acid standards L-Glu (black trace, a), D-Glu (red trace, a), L-Met (black trace, b), D-Met (red 
trace, b), L-Val (black trace, b) and D-Val (red trace, b). The HPLC chromatograms are recorded 






Fig S6. Amino acid analysis of aggregates resultant of UV irradiation (λmax = 305 nm) of mAb 
in L-Arg formulation (blue trace) and after treating with DAAO (b, green trace). a) Amino acid 
standards L-Met (black trace), D-Met (red trace), L-Val (black trace), and D-Val (red trace, a). 







Fig S7. Amino acid analysis of aggregates resultant of UV irradiation (λmax = 305 nm) of mAb 
in L-Arg formulation (blue trace) and after treating with DAAO (b, green trace). a) Amino acid 
standards L-Arg (black trace), D-Arg (red trace), L-Ala (black trace), and D-Ala (red trace, a). 







Fig S8. Amino acid analysis of blank (buffer solution, triplicates) after treating with DAAO. The 
HPLC chromatograms are recorded using a fluorescence detector (λex = 340 nm and λem = 455 
nm). 
























Chapter 4. Understanding the increased aggregation propensity of a light 
exposed IgG1 mAb using hydrogen exchange mass spectrometry, biophysical 


















Biopharmaceutical drugs are a fast growing class of therapeutics, which include peptides, 
recombinant therapeutic proteins such as, insulin, monoclonal antibodies and antibody-drug 
conjugates (ADC).1 In the past 30 years, the number of biopharmaceutical drugs on the market 
increased from 13 to 210, amassing US$163 billion in product sales.2 This increase in demand 
for biologic drugs revolutionized the development pipelines in many pharmaceutical companies. 
In the last decade, there was an increase in the number of biotech products (large molecule 
drugs) in clinical trials by 155%, from 355 in 2001 to 907 in 2012.2 The extraordinary success of 
biotech products is attributed to advantages such as high target specificity, high potency and low 
side effects.1-4 Currently monoclonal antibodies (mAbs) are the largest selling protein 
therapeutics in the market, with a global value of US$86.7 billion in 2015.3  
Therapeutic mAbs are complex glycoproteins that belong to the immunoglobulin (Ig) family. 
Based on the structure of their constant regions, Ig’s are categorized into five groups, IgA, IgD, 
IgE, IgG, and IgM.4-5 Currently, most prevalent group of Ig’s in the market is IgG. IgGs are 
composed of two identical light and heavy chains connected through inter-chain disulfide bonds. 
Each heavy chain is composed of one variable domain (VH) and three constant domains (CH1, 
CH2 and CH3). Each light chain is composed of one variable domain (VL) and one constant 
domain (CL). The variable regions of heavy chain and light chain combine to form the antigen-
binding site (Fab), whereas the constant regions combine to form the fragment crystallizable (Fc) 
domain.4-6 IgGs can be further classified into four subclasses based on the pattern of inter-chain 
disulfide bonds: IgG1, 2, 3 and 4. Among these four subclasses, IgG1, 2 and 4 are used as 




Similar to other protein therapeutics, IgG mAbs are prone to various types of chemical and 
physical instability. Deamidation, oxidation and fragmentation are some of the major forms of 
chemical instability; correspondingly, aggregation, denaturation and precipitation are some of the 
major forms of physical instability.8 These instabilities can lead to loss of activity and, in some 
cases, can cause unwanted immunogenic responses.8-11 The chemical and physical stability of 
therapeutic proteins can be impacted by various external processing-related or handling-related 
factors such as extreme pH, temperature, freeze thaw, excipient impurities, mechanical stress, 
light exposure, and so on.8 
Therapeutic proteins are exposed to light during various stages of their developmental process. 
Chromatographic processes during purification routinely use UV light (280 nm and 214 nm) for 
detection. Light exposure can also occur during storage, fill and finish processes, visual 
inspection and packaging.12 Some types of protein therapeutics are diluted into IV bags before 
administering to the patient, where they can be exposed to ambient light.12, 13 Previous studies 
have identified traces of UVA and UVB light in emissions of fluorescent lamps. 13, 14 
The aromatic amino acids (Trp, Tyr and Phe), peptide backbone and cysteine (disulfide bonds) 
are the principal targets of photodegradation in proteins.12 Photodegradation in proteins begins 
with absorption of light, resulting in excitation of electron to higher energy state (singlet state) 
followed by distinct processes including, relaxation by fluorescence to ground state or undergo 
inter system crossing forming triplet state, reaction with oxygen to generate singlet oxygen (1O2) 
species or excited state photochemical processes such as photoionization. Photoionization leads 
to the release of electron from the residues, resulting in formation of solvated electron (e-aq) and a 
radical cation followed by deprotonation yielding an uncharged radical. The reactive oxidation 
species (1O2) produced on light exposure can initiate photo oxidation in proteins.




example, UV light exposure of an IgG1 mAb induced oxidation of Trp in a complementarity-
determining region (CDR) resulting in significant decrease in its biological activity.16 Recently 
various novel modifications were also identified in IgG1 mAbs due to photodegradation, for 
example, a doubly oxidized His 289 in the Fc region of IgG1,17 a triply oxidized His,18 inter 
molecular His-His crosslinks (220, HC),19 conversion of Trp to Gly and Gly hydroperoxide,20 
and Trp side chain cleavage products.18 Another important consequence of light exposure is 
photoionization, which results in electron transfer to the disulfide bonds, resulting in the 
formation of thiolate and thiyl radical. A pair of thiyl radicals can also be formed via direct 
photolysis (at λ = 254 nm) of disulfide bridges. Thiyl radicals can participate in reversible 
hydrogen transfer reactions with adjacent amino acids leading to the formation of 
dithiohemiacetal, thioether, vinyl thioether crosslinks and epimerized amino acids.21,22 All these 
chemical photodegradation products can act as precursors for physical instability in proteins e.g. 
aggregation, fragmentation etc. 8 
There are a limited number of studies that have examined the effect of light on physical and 
conformational attributes in mAbs. Previously Qi et al.23 have shown formation of yellow color 
in highly concentrated (100 mg/mL) IgG1 mAbs on exposure to light. In the same study, they 
also observed a decrease in biological activity and increase in aggregation and fragmentation 
with increase in duration of light exposure.23 Mason et al.24 studied the effect of pH and UVB 
light (λmax = 302 nm) exposure on protein conformation using various biophysical techniques. By 
DSC analysis, they identified prominent changes in thermal transition temperatures, indicating a 
decrease in conformational stability because of light exposure. While the tertiary structure of the 





Among the various degradation pathways that occur in mAbs on exposure to light, aggregation 
has been one of the major concerns, as protein aggregates are potentially immunogenic.25-27 In 
consequence, it is important to understand the aggregation pathways of mAbs upon exposure to 
light.  
In this study, we aim to understand the underlying mechanism behind the increased aggregation 
propensity of an IgG1 mAb due to UVA light exposure. A mAb sample was exposed to UVA 
light for up to 72 hours followed by isolation of monomer and dimer fractions from the samples 
formed due to light exposure using SEC coupled to a fraction collector. Hydrogen/deuterium 
exchange mass spectrometry (H/D-MS) was used to explore changes in local flexibility of 
isolated monomers, and dimers from the light exposed mAb samples compared to non-light 
exposed control mAb. Biophysical characterization including far- and near-UV CD and DSC 
were used to explore changes in secondary and tertiary stricture and thermal stability of the 
isolated monomers and dimers compared to the control mAb. In conjugation with experimental 
results, computational analyses were also applied to understand potential molecular mechanisms 
of higher order structural changes due to light exposure in mAbA and likely pathways of 
aggregation. The changes observed in higher order structure, thermal stability, and accelerated 
stability are correlated with changes in local flexibility due to photo-induced chemical changes in 
the mAb. Moreover, the possible underlying mechanism of increased aggregation propensity due 








4.2 Experimental methods 
4.2.1 Materials 
 MAbA was expressed and purified at Eli Lilly and company, Branchburg, NJ. Deuterium oxide 
(99+ atom %), tris (2-carboxyethyl) phosphine hydrochloride (TCEP), trifluoroacetic acid (TFA) 
and iodoacetamide (IAA) were purchased from Sigma Aldrich (St. Louis, MO). Monobasic 
sodium phosphate monohydrate, dibasic sodium phosphate anhydrous, sodium chloride, LC-MS 
grade water and acetonitrile (ACN), 10X NUPAGE® reducing agent, Novex sharp pre-stained 
broad range molecular weight marker and SYPRO Ruby Protein Gel stain were purchased from 
Fischer scientific (Hampton, NH). Sequencing grade modified trypsin, PNGase F and Glu-c were 
purchased from Promega (Madison, WI). Guanidine hydrochloride (Gdn-HCl), dithiothreitol 
(DTT), and Tris hydrochloride (Tris HCl) were purchased from Thermo Scientific (Waltham, 
MA). Type I glass vials and stoppers were purchased from Schott Glass (Lebanon, PA) and West 
Pharmaceuticals (West Whiteland, PA), respectively.   
4.2.2 UVA light exposure of mAbA  
 Light exposure experiments were performed using an ICH ES2000 Reach-IN (Environmental 
Specialties, Inc., Raleigh, NC) photo chamber equipped with near-ultraviolet (UVA) lamps and 
cool white fluorescent bulbs to allow exposure to UV and visible spectral regions respectively. 
The near UV lamp has an emission spectrum ranging approximately from 315-400 nm with λmax 
= 350 nm. UVA light exposure was run at factory ‘default’ flux conditions of 22 W/m2. The 




Consistently, 500 µL of mAbA was added to 2 mL type I glass vials capped with autoclaved 
rubber stoppers and placed vertically in the photo chamber. The samples were irradiated for 9 
hours (100% ICH dose = 1X), 24 hours (2.5X ICH) and 72 hours (8X ICH). The chamber 
temperature was controlled at 25 oC throughout the light exposure experiments. 
4.2.3 Size exclusion chromatography (SEC) analysis and fraction collection  
Samples were analyzed using a Dionex (Sunnyvale, CA) high performance liquid 
chromatography system with UV absorbance detection at 280 nm and 214 nm respectively. A 
TSKgel G3000SWxl (Tosoh bioscience, King of Prussia, PA) 7.8 mm x 30 cm column with 5 
µm particle size was used for SEC analysis. The SEC mobile phase contained 47 mM sodium 
phosphate and 300 mM sodium chloride, at pH 7. Isocratic flow conditions at 0.5 mL/min with 
column maintained at 25 oC was used to separate various sized species present in the mAbA 
samples. 75 µg of mAbA were loaded on the SEC column per injection. Fractions corresponding 
to monomer and dimer fractions were collected using the fraction collector connected to the 
system by making approximately 10 injections. The collected fractions were pooled and 
concentrated using Amicon Ultra-15 centrifugal devices with 10,000 MWCO membranes.  
4.2.4 SEC and multi-angle light scattering (MALS) Analysis 
SEC-MALS analysis of mAbA samples was performed using an Agilent (Santa Clara, CA) 1100 
HPLC connected to a Dawn HELEOS II MALS detector in series with Optilab rEX refractive 
index detector (Wyatt Technology Corporation, Santa Barbara CA). 20 µL of mAbA at 2.5 
mg/mL protein concentration was loaded on a TSK gel 3000SWXL column (TOSOH 
biosciences, King of Prussia, PA) connected to the SEC instrument. Data analysis was performed 




4.2.5 Sodium dodecyl sulfate polyacrylamide gel electrophoresis analysis  
Nonreducing and reducing (10X NUPAGE® reducing agent) SDS-PAGE analysis were 
performed on precast Novex 4%-12% Tris-Glycine gels from Invitrogen (Carlsbad, CA). The 
Novex sharp pre-stained broad range molecular weight marker that covers the range of 3.5–260 
kDa was used. 1.25 µg of mAbA was loaded on to each lane and the separation was achieved by 
using 45 mA and 200 V of electricity for 45 min. The gels were stained with SYPRO Ruby 
Protein Gel stain for 30 min, followed by destaining for 60 min. Bio-Rad ChemiDoc XRS+ was 
used to for gel documentation.     
4.2.6 Differential scanning calorimetry (DSC) 
Monomer and dimer fractions in SEC buffer were diluted to 1 mg/mL protein using 47 mM 
sodium phosphate and 300 mM sodium chloride, at pH 6.1 and analyzed with a MicroCal VP-
Capillary DSC instrument (Malvern instruments Inc, Westborough, Massachusetts). Scans were 
collected from 20 to 90 oC at 60 oC/h. The raw DSC data were buffer and baseline subtracted, 
concentration normalized, and then fit to a multi-state model with 3 transitions using the 
MicroCal LLC DSC plug-in for Origin 7.0 software to calculate the thermal transition 
temperatures. The onset temperature of thermal unfolding (Tonset) represent the temperature 
where the heat capacity value reached 0.2 Kcal/mol oC. The reported Tm and Tonset values are an 
average of three independent runs.  
4.2.7 Circular dichroism (CD) analysis 
Far- and near-UV CD data are acquired using a Chirascan Plus CD spectropolarimeter fitted with 




buffer were diluted to 2 mg/mL protein using the same SEC buffer (pH 6.1). The autosampler 
arm was used to load samples from a plate in to the cuvette and then for washing and rinsing the 
cuvette following analysis. Far-UV CD data was acquired in a 0.01 cm pathlength flow-through 
cuvette (Applied Photophysics, Leatherhead, UK) from 190-260 nm wavelength at 1 nm 
bandwidth, step size of 1 nm, and scan time of 1 sec per point. Near-UV CD data was acquired in 
a 0.5 cm pathlength open top flow through cuvette (Applied Photophysics, Leatherhead, UK) 
from 250-350 nm wavelength at 1 nm bandwidth, step size of 1 nm, and scan time of 2 second 
per point. The reported data are average of three repeat scans for any sample. All CD data were 
acquired at ambient room temperature. Water and bovine serum albumin standards were 
analyzed by far- and near-UV CD before and after all sample analyses to confirm no drift of 
instrument performance from historical data or during the sample runs (data not shown). 
4.2.8 Accelerated stability study 
500 µL of protein samples were filled into 2 mL type I glass vials and exposed to UVA light for 
9, 24 and 72 hours, respectively. The light exposed samples, along with controls (no light 
exposure), were then subjected to an accelerated stability study in which samples were stored in 
triplicates at 5 oC, 25 oC and 35 oC and analyzed using SEC after storage for 30 days and 90 days 
along with initial time point samples. 
4.2.9 Intact mass analysis 
Monomer and dimer fractions were diluted into LC-MS grade water to a concentration of 0.5 
mg/mL protein. 100 µL of a 0.5 mg/mL sample was mixed with 2.5 µL of 1 M Tris-HCl buffer 
(pH 8.0) and 2 µL of 2 U/mL PNGase F (Promega, Madison, WI). The mixture was incubated 




buffer) and incubated at 37 °C for 45 min to reduce the disulfide bonds. 0.5 µg of the reduced 
protein was injected onto an Acquity UPLC BEH300 C4 1.7 µm, 1.0 X 50 mm column 
connected to Waters Xevo G2 QTOF (Milford, MA) mass spectrometer operating in ESI positive 
mode. Mobile phases A and B consisted of 0.05% (V/V) trifluoroacetic acid (TFA) in LC-MS 
grade water and 0.04% TFA in LC-MS grade ACN, respectively. A linear gradient of 20-90% 
mobile phase B in 12 min was used at a flow rate of 70 µL/min to elute mAbA from the RPLC 
column (Acquity UPLC BEH300 C4 1.7 µm, 1.0 X 50 mm). Molecular masses were acquired by 
deconvoluting the multiply charged ion peaks using the MaxENT procedure in the MassLynx 
software (Waters, Milford, MA). 
4.2.10 Peptide mapping 
100 µg of mAbA were mixed with 20 µL of 7 M Gdn-HCl, 125 mM Tris-HCl buffer (pH 8.0).  
The disulfide bonds of the mAbA samples were then reduced by addition of 1 µL of 50 mg/mL 
DTT (in 125 mM Tris-HCl buffer) and incubated at 37 °C for 45 min, followed by alkylation 
with 3 µL of 50 mg/mL IAA (in 125mM Tris-HCl buffer) solution in the dark at room 
temperature for 30 min.  170 µL of 100 mM Tris buffer (pH 8.0) was then added to achieve a 
total volume of 300 µL.  The reduced and alkylated samples were digested by the addition of 50 
µL of 0.1 µg/µL sequencing grade trypsin (enzyme: protein 1: 20, w: w) and incubation at 37 oC 
for 2 hours, followed by the addition of 25 µL of 0.1 µg/µL Glu-C (enzyme: protein 1: 40, w: w) 
and further incubation for 2 hours at 37 oC. The digestion was quenched by the addition of 1 µL 
of 50% TFA in water. All the digested samples were analyzed by LC/MS/MSE using a Waters 
nano Acquity UPLC system coupled to a Waters Synapt G2-S mass spectrometer (Milford, MA). 
Tryptic peptides were separated using an Acquity UPLC BEH C18 1.7 micrometer, 1.0 X 150 




m/z 100 and m/z 2000. Data acquisition was achieved in the MSE continuum mode by ramping 
up the collision energy from 22 V to 55 V. Mobile phase A was 0.05% (V/V) trifluoroacetic acid 
(TFA) in LC-MS grade water and mobile phase B was 0.04% TFA in ACN. Peptides were eluted 
with a linear gradient of 1% B to 35% B in 135 min followed by washing the column with 90% 
ACN for 15 min, after which the column was equilibrated with 1% ACN for 8 min with a flow 
rate of 50 µL/min. Trypsin and Glu-C digestion resulted in 95% coverage for both monomer and 
dimer fractions. Peptide mapping data were analyzed using MassLynx software. 
4.2.11 Hydrogen/Deuterium exchange mass spectrometry (H/D-MS)  
The monomer and dimer fractions isolated from control and UVA light exposed mAbA were 
analyzed by H/D-MS using a Waters HDX manager system, connected to a Synapt G2-S mass 
spectrometer. All the starting protein stocks were adjusted to 10 mg/mL protein using 47 mM 
sodium phosphate and 300 mM sodium chloride at pH 6.1. Sample preparation for H/D-
exchange experiments were carried out using a two-arm H/DX PAL robot (LEAP Technologies, 
Carrboro, NC).  4 µL mAbA sample was mixed with 76 µL of labeling buffer (47 mM sodium 
phosphate, 300 mM sodium chloride in 99+ atom% D2O, pH 6.1) in a 1:20 (v/v) ratio to initiate 
H/D exchange. The pH values mentioned here are reported as is recorded using a glass pH probe 
without further conversion to pD. The exchange reaction was quenched at four time points (50, 
100, 1000, 10000 sec) by 1:1 dilution (40 µL) with ice-cold quench buffer (0.4 M TCEP, 4 M 
Gdn-HCl, 200 mM sodium phosphate) at 1 oC resulting in a final pH ~ 2.5. The quenched 
solution is maintained at 1 oC. 20 µL of the quenched solution were immediately injected into the 
sample loop of the refrigerated HDX-Manager compartment, housing the reversed-phase 
column, trap and the pepsin column at 0.5oC during the course of the experiments. The samples 




on a Waters VanGuard precolumn trap (Acquity UPLC BEH C18 1.7 µm) for 5 min at 0.3 
mL/min and then the peptides were separated on a reversed phase column (Acquity UPLC BEH 
C18 1.7 µm, 1.0 x 50 mm) at a flow rate of 50 µL/min. Mobile phase A was 0.1 % formic acid in 
LC-MS grade water and mobile phase B was 0.1% formic acid in LC-MS grade ACN. Peptides 
were eluted with a linear gradient of 3% to 15% mobile phase B in 1 min, followed by linear 
increase from 15% to 40% in next 5 min and directed in to a Waters Synapt G2-S mass 
spectrometer running in the positive ESI mode. The data were acquired in the MSE mode with a 
scan over m/z 255 to m/z 2000, with lock spray correction using leucine encephalin. Two 
additional gradients from 40-90% mobile phase B and 3-90% mobile phase B were built at the 
end of the gradient cycle for each sample injection to allow clean-up of the reversed phase 
column and trap. In addition, after sample digestion through the pepsin column, two cocktail 
mixes of a) 5% acetonitrile, 5% isopropanol, and 20% acetic acid in water and b) 2M guanidine 
hydrochloride in 100mM phosphate at pH 2.5 were injected in 100 µL volumes consecutively to 
pass through the pepsin column to minimize carry-over.31 No major carry-over issues were 
observed following this cleaning protocol for the RPLC column, trap and the pepsin column.     
4.2.12 H/D-MS data analysis  
A peptide list was generated by identifying the resulting peptide segments after online pepsin 
digestion of non-deuterated mAbA sample using the BiopharmaLynx software (Waters), with 
mass tolerance set at 10 ppm for singly charged precursor ions and 30 ppm for MSE fragment 
ions. A total of 118 and 112 peptide segments were identified covering approximately 90% and 
85% of primary sequence of mAbA in monomer and dimer fractions, respectively. HD Examiner 
(Sierra analytics, Modesto, CA) was used to calculate the mass increase due to deuterium uptake 




between mAbA control and light exposed samples (monomer and dimer fractions) were 
identified using a 99% confidence interval for the current data set which was calculated using the 
method of Houde et al.32 H/D exchange data were mapped onto the homology model of mAbA. 
Back-exchange measured using fully deuterated control peptide segments ranged from 18-25 %.   
4.2.13 Homology model of mAbA, sequence, and structural analysis 
Homology modeling was performed based on protein sequence of mAbA in the Molecular 
Operating Environment (MOE) (Chemical Computing Group, Montreal, Canada), using 1HZH 
as a template for full IgG1. Amber10: EHT force field was used for the following structural 
analysis in MOE. Solvent accessible surface area (SASA) and surface exposure (%) for each 
residue was calculated based on the static model structure using the protein properties analysis 
module (MOE). Spatial aggregation propensity (SAP) was computed according to the method 
reported by Chennamsetty et al. (2010) in the Accelrys Discovery Studio 4.0 software (San 
Diego, CA). The modeled structure of mAbA was also prepared and computed for electrostatic 
potential using Accelrys Discovery Studio 4.0 software.  In addition, the online tool 
AGGRESCAN was used to analyze primary sequence for the prediction and evaluation of "hot 
spots" of aggregation in polypeptides. 33 All structure model figures were generated by MOE. 
4.3 Results 
We start by defining three terms that will be used throughout the remainder of the document. 
First, the term “control” refers to a mAbA sample that was directly diluted from the stock 
solution. Second, “dark control” refers to samples that were identically treated as light exposed 
samples, but placed in a card board box in the photo chamber to prevent light exposure. Third, 




4.3.1 UVA light induce increased aggregation with higher exposure time 
MAbA samples in 25 mM sodium phosphate buffer (pH 6.1) were exposed to UVA light for 
various time points: 9 hours (100% ICH dose = 1X), 24 hours (2.5X ICH) and 72 hours (8X 
ICH). The apparent molar mass of the various sized species generated due to light exposure were 
independently confirmed using SEC-MALS analysis (Supplementary Material, Fig. S1). The 
percent of dimers and higher molecular weight species (HMWS) increased with increasing 
duration of UVA light exposure (Fig 1a). SEC connected to a fraction collector was used to 
isolate both monomer and dimer fractions. The amount of dimers formed in control and light 
exposed mAbA samples ranged from 4 – 12%, as measured by SEC. Dark controls contained 
similar amount of aggregates as the control samples. Approximately 10 injections of each 
original mAbA sample were made for isolation of monomer and dimer species followed by 
pooling and concentrating the samples to obtain enough protein quantities for future 
experiments. The purity of the collected fractions was determined using analytical SEC. 
Monomer fractions (Fig. 1b) were 98% pure and eluted at approximately 16 min, whereas the 
dimer fractions (Fig. 1c) were 94 – 96% pure with traces of monomer species and eluted at 14 
min. Purified fractions were always stored at 2-8 oC until further analysis.   
Comparison of non-reducing and reducing SDS-PAGE (Supplementary Material, Fig.S2) 
indicates formation of non-reducible covalent species in light exposed samples. Formation of 
higher molecular weight species (HMWS) increased (appearance of new bands above the heavy 
chain band) with increase in the duration of light exposure, which is in agreement with the SEC 
data. Along with HMWS there was a parallel increase in the formation of fragments, which are 
detected as lower molecular weight bands observed below the band of intact protein in non-




4.3.2 UVA light induced oxidation of selective Met residues in mAbA 
Both monomer and dimer fractions were analyzed using LC-MS to determine the effect of light 
on chemical degradation of mAbA. Through intact mass analysis (Supplementary Material, Fig. 
S3), peaks with a mass increase of ~32 Da were identified exclusively on HCs of mAbA samples 
exposed to light. The intensity of these additional peaks increased with the increase in duration 
of light exposure. Less intense peaks with a mass increase of ~16 Da were also observed. Peptide 
mapping was used to identify the distribution of modifications. On analysis, selective peptides 
with methionine (Met) showed an additional peak with mass increase of 16 Da. It was confirmed 
by MS/MS that the mass increase was due to the oxidation of Met residues to methionine 
sulfoxide (MetSO). The extent of oxidation was determined by dividing the extracted ion 
chromatogram (EIC) peak areas of the MetSO containing peptides by the total peak areas of 
MetSO containing peptides and non-oxidized Met containing peptides.  
There are six Met residues in the heavy chain of mAbA, out of which Met 257 and Met 433 were 
extensively oxidized in both monomer (Fig. 2a) and dimer (Fig. 2b) fractions.  The extent of Met 
oxidation increased with the duration of light exposure for both monomer and dimer fractions. 
Table. 1 summarizes oxidation levels of Met residues in UVA light exposed mAbA (monomer) 
as well as the calculated solvent accessible surface area (SASA) of the respective Met residues. 
There were some peptides which showed probable low levels of Tyr and His oxidation, but lack 
of good MS/MS fragmentation to further confirm the modification, limited us in identifying 
these modifications.  




4.3.3 UVA light reduced thermal stability of mAbA monomer and dimer 
fractions 
Thermal unfolding by DSC was used to compare the conformational stability of mAbA 
monomer and dimers isolated from control and UVA light exposed mAbA samples. Figure 3a 
shows a representative DSC thermograms of mAbA (1 mg/mL, pH 6.1 in SEC buffer), which 
display three distinct thermal transition temperatures denoted as Tm1, Tm2, and Tm3. Values for 
the onset temperatures (Tonset) (Table. 2) were also determined. A gradual decrease in Tonset and 
Tm1 were observed for monomers and dimers (Table. 2, Supplementary Material, Fig.S4) 
collected from mAbA exposed to increasing doses of UVA light. 72 hours UVA light exposure 
caused ~ 11 oC decrease in Tonset, ~ 1.4 
oC decrease in Tm1,  ~ 0.5 
oC decrease in Tm2 in both 
monomer and dimer fractions compared to the control. ~ 0.5 oC and ~ 0.2 oC decrease in Tm3 are 
also observed for monomer and dimer fractions compared to the control mAb.  
4.3.4 UVA light exposure induced changes in tertiary structure of mAbA 
dimers 
The near-UV CD data for the monomer and dimer fractions (Fig. 3a, 3b) of mAbA show changes 
due to light exposure compared to the control. The magnitude of the changes are higher than 
usual instrument variability, and hence indicate changes in tertiary structure of mAbA due to 
UVA exposure. The differences are very distinctive in dimer fractions (Fig. 3b) collected from 
UVA light exposed samples. No differences in near UV-CD spectra was observed between 




The far-UV CD data for the monomer and dimer fractions of mAbA (Supplementary material, 
Fig.S5) show no major changes due to increasing UVA light exposure compared to the control 
indicating no major change in secondary structure of the monomer/dimer fractions. All the 
spectra displayed intense negative band between 215-220 nm demonstrating β-sheet rich nature 
of mAbA. No difference in far UV-CD spectra was observed between control monomer and 
dimer samples (data not shown).  
4.3.5 UVA light exposure decreases accelerated storage stability of mAbA  
The impact of pre-exposure to UVA light was assessed on accelerated storage stability of mAbA 
samples. The protein samples were stored in stoppered type I glass vials at three temperatures (5 
oC, 25 oC and 35 oC) for up to 90 days after the light exposure, and analyzed by SEC to quantify 
the percent of monomer, aggregates and fragments species that were generated. SEC 
chromatograms of mAbA were analyzed immediately (day 0) after light exposure (9 hours, 24 
hours and 72 hours). While non-photo irradiated samples contained predominantly monomer 
(Fig. 4b), with low levels of aggregates (4.2%, Fig. 4a) and fragments (0.16%, Fig. 4c), whereas 
mAbA samples exposed to UVA light for 9, 24 and 72 hours contained 6.52% (± 0.32), 8.81% (± 
0.47) and 12.82% (± 0.42) of aggregates (Fig. 4a) respectively and 0.27% (± 0.027), 0.39% (± 
0.031)  and 0.59% (± 0.029) fragments (Fig. 4c), respectively at day 0.  
Upon accelerated storage, the light exposed mAbA samples had a major decrease in monomer 
content and elevation in aggregate and fragment content. For example, the control sample 
showed only slow increase of aggregate content from 4.2% (± 0.33) at day 0 to 4.57% (± 0.27), 
4.7% (± 0.30) and 4.9% (± 0.39) respectively, upon incubation at 5 oC (black solid line), 25 oC 




photo-irradiated sample showed a rapid increase in aggregate content from 12.82% (± 0.71) at 
day 0 to 19.89% (± 0.93), 23.86% (± 0.56) and 25.69% (± 0.82) on incubation for 90 days at 5 
oC (blue solid line), 25 oC (blue dashed line) and 35 oC (blue dotted line), respectively (Fig. 4a). 
Similarly, other stressed (9 hours and 24 hours UVA light exposed) samples also exhibited rapid 
decrease of monomer and increase of aggregate content, compared to control samples (Fig. 4).  
4.3.5 H/D-MS analysis of mAbA monomers and dimers 
H/D-MS analysis was used to evaluate the changes in local dynamics of mAbA due to UVA light 
exposure. MAbA monomer and dimers fractions generated due to 72 hours UVA light exposure 
along with the control mAbA monomer sample were labeled with deuterium using deuterated 
solutions containing 47 mM sodium phosphate and 300 mM sodium chloride (pH 6.1) in 99+ 
atom % D2O at 25 
oC. The exchange was quenched at different time points (50 sec, 100 sec, 
1,000 sec and 10,000 sec), followed by proteolysis using a pepsin column and analysis by LC-
MS. A total of 118 and 112 peptide segments were identified covering approximately 90% and 
85% of the primary sequence in the monomer and dimer fractions, respectively, collected from 
mAbA which was exposed to light for 72 hours. 
Deuterium uptake plots were generated for each peptide by plotting the mass increase for each 
peptide vs exposure time (seconds) in D2O.  Fig. 5 shows deuterium uptake plots of six 
representative peptide segments from mAbA control monomer, and monomer and dimers from 
72 hours light exposed mAbA. Comparison of the H/D exchange profiles of 118 peptic peptide 
segments showed no significant changes in deuterium uptake for majority of the peptide 
segments compared between control and 72 hours UVA light exposed monomer or dimer 




and HC 301–323 in the CH2 domain showed increased in deuterium uptake in both UVA 
exposed monomer and dimer samples compared to the control monomer. For example, in 
monomer fractionated from 72 hours UVA light exposed mAbA the HC 247–256 segment 
(peptide number 53) in the CH2 domain exchanged more quickly with largest difference, relative 
to the control evident at 50 sec. In the CH2 domain there were also a series of overlapping 
peptide segments (Supplementary Material, Fig.S6) covering HC 242-256, which are located at 
the N-terminus of the CH2 domain displayed increased deuterium uptake in UVA light exposed 
monomer and dimer when compared to control monomer.    
H/D-MS analysis of dimer fractions revealed several segments with increased deuterium uptake, 
(Fig.5 and Supplementary material, Fig.S7) HC 116-125, and HC 155-170 in CH1 domain, HC 
242-256, and HC 301-315 in CH2 domain and HC 376–385 in CH3 domain indicating regions 
with decreased strength of H-bonding or increased solvent exposure due to UVA light induced 
chemical changes. Analysis also revealed several segments, HC 51–59 in VH domain, HC 204–
213 in CH1 domain and LC 95–99 in VL domain with decrease in deuterium uptake as compared 
to control monomer.  
Differential exchange plots were used to visualize and estimate the impact of light induced 
chemical changes on H/D exchange across all the mAbA peptides. The relative mass difference 
(Δm) is the difference in average mass of a peptide segments between two states, (eg. state 1: 
light exposed and state 2: control). 
Ordinal numbers (peptide numbers) were assigned to each peptide segment based on the 
ascending order of sequence midpoint of each peptide segment from the N-terminus to the C-




axis vs the peptide number on the horizontal axis of the difference plots (Fig. 6). MAbA 
segments with positive Δm indicate regions of increased deuterium uptake, implying increase in 
local flexibility due to UVA light exposure, whereas negative Δm indicate regions of decreased 
deuterium uptake implying decrease in local flexibility. A 99% confidence interval of ± 0.59 Da 
(Supplementary material, Fig.S8) was calculated based on the standard deviations from the entire 
dataset and is represented by a black horizontal dashed line in Figure. 6. A measured Δm greater 
or smaller than 0.59 Da for at least one labeling time point indicate a significant difference in 
local flexibility in the corresponding peptide segment. Most regions of mAbA monomers or 
dimers did not have any significant changes in flexibility due to UVA light exposure, whereas 
few segments had statistically significantly changes. 
Following analysis, the segments showing significant changes in deuterium uptake are color 
coded on to the homology model of mAbA (Fig. 7a, 7b). Regions with significant increase and 
decrease in deuterium uptake are color coded with red and blue, respectively.  
4.3.7 Structure-based and sequence-based computational analysis of mAbA  
Three-dimensional structure based analysis of mAbA including SAP (spatial aggregation 
propensity), SCM (spatial charge map) and other molecular descriptors were calculated 
(Supplementary material, Fig.S9). The results indicated that mAbA bear hydrophilic surface 
overall, with a net charge of 9.3 when calculated at pH 6.1. Furthermore, there is no strong 
negatively charged patch or charge imbalance identified on the surface of the mAbA by SCM 
analysis or electrostatic potential analysis. The three regions with decreased deuterium uptake 
identified from dimer sample, one (HC 204-213) is the outer β-sheet stretch located on CH1 




sheet on CH1 (Fig. 8b). The other two regions with decreased uptake are located on the Fv 
domain; composed of a partial CDR-H2 loop and CDR-L3 loop (Fig. 8a). A closer look of these 
regions reveals that charge and polar residues (D, E, K, Y, N) are dominant on the surface, with 
the exception of a surface exposed Trp residue. On the other hand, plotting the regions with 
increased deuterium uptake (either monomer or dimer) indicates that they are predominantly 
located at the constant regions of mAbA (CH1, CH2 and CH3) and mostly buried or partially 
buried. HC 116-125 is the linker connecting the Fv to the CH1 domain, it is known to be a 
flexible region involving elbow movement of the Fab domain. HC 151-170 is a long stretch 
consisting of two anti-parallel β-sheets, located at the center of CH1 domain. The other three 
regions (major increase of uptake) cluster around the inner core of the CH2 domain (2 β-sheets), 
plus a nearby loop on the top of the CH3 that interfacing with the CH2 domain. The β-sheet (HC 
242-256) with the most significant increase in deuterium uptake is directly adjacent to the 
carbohydrates packed between the two CH2 domains of the Fc dimer. The last residue of this 
region (HC 242-256) is followed directly by Met 257, located at the CH2-CH3 elbow. Met 257 
and Met 433, the top two residues showing highest rate of oxidation upon photo-stress of mAbA 
are three-dimensionally close with each other.  
In addition to the spatial aggregation propensity analysis, AGGRESCAN was used to probe the 
aggregation prone sequences in the constant domains of mAbA based on the primary sequence. 
The hot spots identified by AGGRESCAN included HC 144-155, HC 176-193, HC 243-248, HC 
303-316, and HC 367-378, which are then plotted on the mAbA homology model (Fig. 7c). In 
comparison with the plot based on the HDX results of dimer (Fig. 7b), several AGGRESCAN 






Protein aggregation represents a process during which two or more protein molecules 
(monomers) associate to form stable complexes. Aggregates may be tethered by strong non-
covalent/covalent forces, which may require a marked level of conformational alteration 
(unfolding or misfolding) in order to expose highly aggregation-prone sequence of amino acids 
(aggregation “hot spots”), which may form strong inter-protein contacts between the 
monomers.34 The aggregation propensity of a given protein can be influenced by its 
environmental factors such as, the solution pH, ionic strength, concentration of co-solutes, 
mechanical stresses, exposure to light, etc.8  
The main aim of this study was to investigate the molecular mechanism of increased aggregation 
propensity of an IgG1 mAb following exposure to UVA light. Light exposure of protein 
therapeutics has been known to induce oxidation, fragmentation, covalent cross-links, 
discoloration, yellow color formation and aggregation.16-24 In this study, a monoclonal antibody 
of IgG1 subclass, mAbA was exposed to UVA light for three different time points: 9 hours 
(100% ICH), 24 hours (2.5X ICH) and 72 hours (8X ICH). SEC was used to separate and collect 
monomer and dimer fractions of the UVA exposed mAbA sample, and the fractions were 
analyzed by a variety of techniques to monitor their conformational, physical and chemical 
stability as well as aggregation propensity on storage. A dependence of duration of light 
exposure on the rate of aggregation of mAbA on accelerated storage was observed from SEC 
(Fig. 1a) and SDS-PAGE (Fig. S2) data. The extent of aggregation increased with an increase in 
the duration of light exposure. Non-reducible covalent species with molecular weight ranging 




The amount of non-reducible species also increased with increase in duration of light exposure, 
the trend being 9 hours < 24 hours < 72 hours.   The high degree of covalent character in UVA 
light exposed mAbA can be rationalized by the formation of photo induced non-reducible 
covalent crosslinks. Previously Liu et al. 19 have discovered formation of photo-oxidative cross-
links across two identical conserved His residues on two separate heavy chains. In other studies, 
Mozziconacci et al. 21, 22 have identified formation of thioether, vinyl thioether and 
dithiohemiacetal crosslinks. The cleavage and formation of these C-S (carbon-sulfur) crosslinks 
may occur through photo induced homolytic cleavage of the disulfide bonds. These type of 
covalent crosslinks could account for the multiple non-reducible higher molecular weight species 
detected by reduced SDS-PAGE analysis.  
The majority of IgG1 and IgG2 class mAbs have two conserved Met residues, Met 257 and Met 
433 located in the CH2 and CH3 domains, respectively. In this study, UVA light exposure of 
mAbA resulted in extensive oxidation of Met 257 and Met 433 in both monomer (Fig. 2a) and 
dimer (Fig. 2b) fractions. Similar observations were made by Liu et al.35 where they observed 
preferential oxidation of Met 257 and Met 433 in another light exposed IgG1 mAb. The 
oxidation of these Met residues [to Met sulfoxide (+16) or Met sulfone (+32)] has been shown to 
decrease circulation half-life, protein A binding, FcRn binding and thermal stability.36-38 
Oxidation of mAbA upon light exposure may involve formation of reactive oxygen species 
(ROS) such as: singlet oxygen, superoxide and hydrogen peroxide, which are shown to oxidize 
the proteins.12, 39 For example, Alavattam et al.39 have shown that the surface exposed Trp 
residues are capable of transferring light energy to oxygen, converting it to various ROS and 




In this study, we observed extensive oxidation of Met 257 and Met 433 residues, with SASA 
values of 27.96 and 0, respectively (Table.1). Residues that are more solvent exposed were 
anticipated to be more available for chemical degradation. On contrary, Met 433 with zero SASA 
was highly oxidized. This could be because of its close proximity to Met 257 (highly oxidized), 
which may induce oxidation of Met 433 due to small conformational changes due to 
oxidation.40,41 
To understand the effect of light exposure on mAbA and to study the underlying mechanism of 
aggregation, we investigated the conformation of mAbA before and after UVA light exposure. 
DSC is normally used to test the thermal stability of proteins.42,43 In our study, thermograms of 
intact mAbA revealed three transitions. The transition with largest experimental enthalpy 
represents unfolding of the Fab segment, while the second and third transition temperatures 
represent unfolding of CH2 and CH3 domains, respectively.
42,43 From the data (Table. 2), it is 
evident that the UVA light exposure affects the thermal stability of mAbA. There was decrease 
in Tonset and Tm1 by ~11 
oC and ~1.4 oC, respectively in 72 hours UVA light exposed monomer 
when compared to control monomer and decrease in Tonset and Tm1 by ~11 
oC and ~1.4 oC, 
respectively in dimer fractionated from 72 hours UVA light exposed sample when compared to 
control dimer. Monomer and dimer fractions separated from mAbA samples exposed to 
increasing durations of UVA light, showed decrease in Tonset and Tm1 values, while the Tm2 and 
Tm3 unfolding transitions showed relatively smaller decreases (~ 0.5 
oC). Larger decreases in 
Tonset and Tm1 values indicate changes in conformational stability in the Fab domain resultant of 
light exposure.    
Analyzing the dimer species fractionated from UVA light exposed samples, near-UV CD (Fig. 




that, the environment of the disulfide bonds, and aromatic residues in the antibody are impacted 
by the chemical changes on UVA light exposure. Methionine oxidation along with changes in 
dynamics could cause disruption of tertiary structure of light exposed dimer samples when 
compared to control dimer. However, only minor changes in the magnitude of MRE was 
observed and no new peaks or deletion of peaks were observed indicating the changes in tertiary 
structure of mAbA was not extensive due to light exposure. No changes were observed by far 
UV-CD between the UVA light exposed monomer, dimer and the control indicating insignificant   
changes to the secondary structure.   
To understand the impact of UVA light exposure on accelerated storage stability, a study was 
performed, where mAbA samples were exposed to various durations of light exposure (9 hours, 
24 hours and 72 hours) followed by incubation at different temperatures (5 oC, 25 oC and 35 oC) 
for up to 90 days and later analyzed using SEC. The results (Fig. 4) indicate that 72 hours of 
light exposure resulted in significant increase in aggregation from approximately 12.82% at time 
zero to 25.69%, as compared to increase from 4.2% to 4.7% for control sample on storage at 35 
oC for 90 days. This data proved that chemical changes imparted to the mAb due to light 
exposure significantly increase the aggregation propensity of mAbA on accelerated storage 
conditions.  
4.4.1 Identification of potential aggregate interfaces in dimers formed 
resultant of UVA light exposure 
H/D-MS analysis of dimers fractionated from 72 hours UVA light exposed mAbA revealed (Fig. 
5) peptide segments with increase in protection against deuterium uptake. Three segments HC 




the dimer fraction. Segment HC 204-213 is located in the CH1 domain, whereas HC 51–59, and 
LC 95–99 are located in the Fab arm. Interestingly, HC 204-213 segment shares some of the same 
residues as in HC 206-242 has been previously identified by Iacob et al.30 as an aggregation 
interface in a native (not result of any stress) IgG1 mAb dimer, also showing protection towards 
exchange in dimer form compared to monomer.  
Identification of segments with decrease in uptake in Fab and CH1 regions demonstrate probable 
formation of Fab-Fab or Fab-CH1 or CH1-CH1 interfaces in the dimers. However, long distance 
interactions between specific segments cannot be ruled out based on the results of H/D exchange 
results alone. Previously several groups have examined protein-protein interfaces of antibody 
aggregates. For example, Arora et al.44 have identified the interface of reversible self-association 
in the Fab region in IgG1 mAb at high concentration. Hydroxyl radical foot printing was used to 
locate the interface of the antibody dimer by Deperatla el al.45. Zhang et al.46 identified Fab-Fab 
interactions in the CDR region in irreversible aggregates generated resultant of heat exposure.  
4.4.2 Integrating experimental data with structural and computational 
analysis 
Comparison of the H/D-MS data of monomer and dimer plotted on the mAb structure (Fig. 7a, 
7b) revealed one interesting feature, which is that the additional peptide regions with increased 
uptake (on dimer species) reside on area of inter-domain interfaces. HC 116-125 is the linker 
between VH and CH1 domain; and HC 376-385 is a turn between the two β-sheets of CH3 
domain, contributing to the CH2-CH3 interface. It suggests that the active regions (increase 
uptake) spread from one domain to another domain through either linker or direct contacts.  In 
combination of the findings from the near-UV CD experiment (Fig. 3a, 3b), which indicated 




perturbation in monomer (intra-domain) likely propagate to other domains in dimer species 
(inter-domain). This could be the result of dimer formation or one leading reason of dimer 
association. 
The common implication of decreased uptake is that the regions are protected by protein-protein 
interactions. The three regions with decreased uptake in dimer species are surface exposed 
peptide segments, all on the Fab domain (Fig. 7b), suggesting Fab-mediated dimer formation. 
Among them, HC 51-59 and LC 95-99 are part of CDR-H2 and CDR-L3 loop, unique to mAbA. 
Three-dimensionally, they form a connected stretch on the Fab CDR surface, which was named 
as site 1 (Fig. 8c). The global surface feature of mAbA is hydrophilic based on SAP, SCM and 
electrostatic potential analysis. Zooming into the site 1 area on the Fab CDR surface, there is a 
small but strong hydrophobic spot (Tyr 94 of LC) standing out in the region of LC 95-99 (Fig. 
8c).  The rest of the surface in this protected area consists mostly charged and polar resides (K, 
D, E, Y). The SAP hotspot (Tyr 94 of LC) may drive dimeric association. Yet we cannot rule out 
intermolecular interaction of mAbA through charge or polar interactions. The third peptide 
region with decreased uptake (HC 204-213) is further down in CH1 domain that precedes the 
upper hinge of mAbA and was named site 2 (Fig. 8d). Taking into account the locations of these 
protected regions and the geometry of IgG structure, more than one potential orientations likely 
co-exist for the dimeric association for mAbA after UVA exposure. Dimeric interfacing through 
site 1 is likely a head to head contact by the Fab arms of two mAbA, which resembles the 
elongated form described by Plath et al.47. On the other hand, dimer association through the site 
2 is likely the side to side interaction through CH1 domain, an example shown as the compact 
form by Plath et al.47 Presumably site 2 dimer association is common to all IgGs, whereas site 1 




 In this study, the hotspots identified by AGGRESCAN based on sequence analysis coincide 
with several regions with increased deuterium uptake, which are also the hydrophobic cores of 
the constant domains. The two methionines with highest oxidation upon UVA light exposure 
(Met 257 and Met 433) are located at the elbow regions between CH2 and CH3 domains.  Met 
257 is directly connected to the strand (HC 242 - 256, highest uptake). Met 433 is close to the 
strand (HC 376 - 385, increased uptake) in CH3. It is plausible that the oxidation of Met 257 and 
Met 433 upon light exposure induces local perturbations and populates firstly to regions of 
proximity within the CH2 domain and CH3 domain, displaying increased uptake. If local 
structural changes lead to domain unfolding, the AGGRESCAN predicted hotpots could be the 
sites that are prone to start a cascade of events that lead to high molecular weight aggregate 
formation. 
4.4.3 Changes in thermal stability do not correlate with local flexibility 
DSC data showed small changes in Tm2 and Tm3 in the 72 hours light exposed sample, indicating 
that the chemical changes and the significant increases in flexibility observed in the CH2 and CH3 
domains have minor impact on thermal stability of these domains in mAbA. However, DSC 
indicated somewhat larger changes in Tonset and Tm1 in the 72 hours light exposed monomer 
sample compared to the control monomer in spite of no major chemical changes seen in the Fab, 
except a significant increase in local flexibility of the 147-156 segment in the CH1 domain. 
Several other segments in the Fab experienced changes in flexibility in the dimer, however no 
major changes in thermal stability was observed between the dimer and monomer fractions. This 
shows a total lack of correlation between large changes in thermal stability and local flexibility 




4.4.4 Changes in local flexibility of ‘aggregation hotspots’ induce higher 
aggregation 
UVA light exposure caused significant increases in local flexibility in two particular domains: in 
the CH1 domain (HC 147 – 156), and in the CH2 domain (HC 242-256 and HC 301-323) of 
monomer fractionated from 72 hours UVA light exposed mAbA (Fig. 5). In contrast, significant 
increases in local flexibility in dimer fractionated from 72 hours UVA light exposed mAbA were 
identified in three particular domains: in the CH1 domain (HC 116 – 125, and HC 151- 170), in 
the CH2 domain (HC 242-256, and HC 301-323), and in the CH3 domain (HC 376–385). The 
largest increase in local flexibility was observed in the two specific segments of the CH2 domain 
that are predicted to be aggregation prone by the sequence based predictor (AGGRESCAN). 
These hydrophobic segments in the CH2 domain of mAbA likely initiate the aggregation 
pathway. Previously several studies have shown that increased flexibility in the same segments 
in the CH2 domain as is observed in this study is correlated with loss of stability in IgG1 mAbs. 
48-50 A conformational comparison between mAb dimer and monomer by Iacob et al.30 revealed 
rapid deuteration of the same segment in the CH2 domain in the dimer demonstrating an increase 
in local flexibility in this region on dimer formation. Other researchers have shown that 
oxidation of Met 257 in IgG1 mAbs resulted in increased deuterium uptake in an 11-amino acid 
segment (FLFPPKPKDTL) that also cover the 242-256 segment in the CH2 domain in mAbA 
located immediately before Met 257.32,41 It has been postulated that oxidation of Met 257 and 
Met 433 increase the distance between two sulfur atoms, thus disrupting the hydrophobic 




Photo-stability is routinely screened for new candidate mAbs in preclinical development. 
Generally, an appropriate control strategy is designed for candidates that show greater 
degradation liability on photo-exposure. Exploring the correlations between photo-induced 
damage such as oxidation in case of mAbA, conformational and accelerated storage stability, 
changes in local flexibility, and computationally predicted aggregation hotspots can identify 
aggregation prone sequences in a mAb. Such information may be used during protein 
engineering to reduce the potential for long term aggregation propensity thereby increasing the 
safety of these types of biotherapeutics. Future studies may be designed with mAbs looking at 
the impact on aggregation propensity due to different types of light-induced chemical 
degradation. One way to limit oxidation in such studies will be to do the photo-exposure 
experiments in sealed vials containing only nitrogen in the headspace. Moreover, the similarity 
of the data presented in this report with data from other mAbs can also produce platform learning 
for IgG1 mAbs.  
4.5 Conclusions 
Comprehensive understanding of aggregation propensity of protein pharmaceuticals is a vital 
task in development of protein therapeutics in the biopharmaceutical industry. In this study, we 
demonstrated use of H/D-MS to explore changes in local flexibility due to UVA light exposure 
on an IgG1 mAb accompanied with computational analysis for identification of aggregation 
prone regions, and biophysical analysis using circular dichroism and differential scanning 
calorimetry to explore changes in higher order structure and thermal stability. Our results 
indicate that UVA light exposure induced methionine oxidation, caused larger changes in the Fab 




three segments in the CH2 and CH3 domains in the monomer and dimer. We also identified 
formation of possible Fab-Fab and Fab-CH1 interaction interface in dimers, formed resultant of 
UVA light exposure. Computational analysis identified potential aggregation prone regions in 
CH2 and CH3 domains of the mAbA. Increased deuterium exchange was specifically observed in 
two of these aggregation hotspots (HC 242 – 256, and HC 376 - 385) in the 72 hours light 
exposed mAbA monomer and dimer fractions. Hence increased local flexibility in the CH2 
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t 34                                   HC                                    2.8                                       0.002 
     
                   Met 83                                   HC                                     0                                         2.054 
 
                   Met 109                                 HC                                  17.37                                        0 
 
                   Met 257                                 HC                                   56.25                                   27.96 
 
                   Met 363                                 HC                                    4.46                                    47.21    
 
                   Met 433                                 HC                                   57.74                                      0 
 
Table 1. Sites of methionine oxidation in UVA light exposed mAbA samples. 
 
Sites of methionine oxidation identified by LC-MS/MS analysis in mAbA samples exposed to 
UVA light   for 72 hours. The solvent accessible surface area (SASA) was calculated based on 
































                                    Tonset (o C)                Tm1 (o C)                      Tm2 (o C)                     Tm3 (o C) 
   
Sample type            Mean   SD   ∆Tonset      Mean   SD     ∆Tm1        Mean    SD    ∆Tm2      Mean   SD     ∆Tm3    
Monomer 
Control                  54.5     0.3     -              68.6     0.5      -              73.7      0.1      -              82.2   < 0.1     -                          
UVA 9 hrs             51.1     0.7   -3.4          67.9    < 0.1   -0.7          73.6      0.3     -0.1          82.1   < 0.1   -0.1 
UVA 24 hrs           47.2     0.6   -7.3          67.7    < 0.1   -0.9          73.5      0.2     -0.2          82.0     0.2    -0.2 
UVA 72 hrs           43.5     0.4   -11           67.2     0.12   -1.4          73.2   < 0.1     -0.5          81.7     0.2    -0.5           
Dimer    
Control                  55.9     0.4      -            68.1    < 0.1      -            73.6    < 0.1      -             82.1    < 0.1     - 
UVA 9 hrs             52.1     0.4    -3.8         67.5    < 0.1    -0.6         73.3      0.2     -0.3          82.0     0.6    -0.1 
UVA 24 hrs           49.2     0.9    -6.7         67.2    < 0.1    -0.9         73.2     < 0.1   -0.4          81.9   < 0.1   -0.2        
UVA 72 hrs           45.4     0.4    -10.5       66.7    < 0.1    -1.4         73.1     <0.1    -0.5          81.9   < 0.1   -0.5 
 
Table 2. Thermal onset temperature (Tonset) and Thermal melting temperatures (Tm1, Tm2, and Tm3) 
for monomer and dimer fractions collected from UVA light exposed mAbA samples as measured by DSC 
mAbA solution at 1 mg/mL contained 47 mM sodium phosphate and 300 mM sodium chloride at pH 6.1.  
The difference in melting temperature (∆Tm) was obtained from Tm, light exposed – Tm, control.  





























Figure 1. SEC analysis of mAbA samples exposed to UVA light. (a) Overlay of SEC 
chromatograms of mAbA exposed to increasing durations of UVA light. Samples were prepared 
in 25 mM sodium phosphate buffer (pH 6.1), without light exposure (control) (black trace) and 




trace). Overlay of SEC chromatograms showing purity of monomer (b) and dimer (c) fractions 
obtained after several injections and concentration of mAbA samples using SEC fraction 
collector. Each injection contained 125 µg of mAbA and monitored at 214 nm. 
 
Figure 2. LC-MS analysis: Characterization of monomer and dimer fractions obtained from 
UVA light exposed mAbA samples. Correlation between methionine oxidation levels and 
duration of UVA light exposure, in (a) monomer and (b) dimer fractions. Error bars represent 











Figure 3.  Near-UV spectra (n=3) of monomer (a) and dimers (b) isolated from mAbA samples 







Figure 4. Effect of pre-exposure to UVA light on stability of mAbA during storage under 
accelerated conditions (5 oC, 25 oC and 35 oC) monitored by SEC. Changes in stability is 
represented as (a) % monomer, increase of (b) % aggregates and (c) % fragments. Error bars 





Figure 5. Deuterium uptake curves of six peptide segments from different regions of monomer 
and dimer fractions isolated from control mAbA and mAbA sample exposed to UVA light for 72 
hours. Peptide segment identity is shown on each plot. The vertical axis on each graph represent 
the maximum possible exchange for each segment. The error bars represent standard deviation 








Figure 6. Relative mass difference (Δm) for all peptide segments of UVA light exposed (for 72 
hours) mAbA, compared with control (no light exposure) monomer as measured by H/D-MS. 
Each vertical bar represents the mass difference of the average deuterium uptake of each peptide 
segment, at four different exchange time points (50, 100, 1000, and 10000 s). The x-axis 
represents the peptide number, arranged in ascending order starting with N-terminus of heavy 
chain and ending with C-terminus of the light chain. The horizontal dotted line represents the 
99% confidence limit ( 0.59 Da) for a significant mass difference. The domain locations of the 



















Figure 7. Effect of UVA light exposure on deuterium uptake of various segments of mAbA as 
measured by H/D-MS and plotted onto the homology model of mAbA. The color code is 
acquired from comparison of average deuterium uptake of monomer and dimer species 
fractionated from mAbA exposed to UVA light for 72 hours, compared with mAbA control 
monomer. The peptides segments that showed significant differences are indicated on the 
homology model. (a) Monomer, (b) Dimer and (c) Aggregation prone regions identified by 

















Figure 8. Effect of UVA light exposure on deuterium uptake of various segments of mAbA as 
measured by H/D-MS and plotted onto a homology model of the mAbA Fab CDR surface (a, b). 
The spatial aggregation propensity (SAP) values at R = 5 Å are mapped onto the molecular 






Fig. S1 SEC-MALS analysis of mAbA (1 mg/mL) (a) control and (b) exposed to UVA light for 
72 hours. The left vertical axis is labeled as molar mass (g/mol). The solid vertical lines represent 
UV absorbance at 280 nm and horizontal line represents light scattering intensity. The average 






Fig. S2 Non-reduced and Reduced SDS-PAGE of mAbA samples exposed to increase in 
durations of UVA light: lane 1 molecular weight (kDa) standards, lane 2 control sample, lane 3 
exposed 9 hours sample, lane 4 exposed 24 hours sample, lane 5 exposed 72 hours sample and 











Fig. S3 Deconvoluted mass spectra of the heavy chain resultant of reduction of mAbA (a) 












Fig. S4 DSC thermograms of mAbA exposed to UVA light. (a) Illustration of curve-fitted DSC 
thermograms for mAbA with Tm1, Tm2 and Tm3. Conformational stability of monomer (b) and 






Fig. S5 Far-UV spectra (n=3) of (a) monomer and (b) dimers isolated from mAbA samples 





Fig. S6 Deuterium uptake curves for the segments from monomer fractionated from mAbA 
exposed to UVA light for 72 hours vs control monomer. Peptide segments containing oxidized 
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Fig. S7 Deuterium uptake curves for the segments from dimer fractionated from mAbA exposed 
to UVA light for 72 hours vs control monomer. Peptide segments containing oxidized Met 
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Fig. S7 Deuterium uptake curves for the segments from dimer fractionated from mAbA exposed 
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Fig. S7 Deuterium uptake curves for the segments from dimer fractionated from mAbA exposed 
to UVA light for 72 hours vs control monomer. Peptide segments containing oxidized Met 





Fig. S8 Distribution of standard deviations for the mass increase of all peptides across all time 













Fig. S9 Spatial aggregation propensity (SAP) for mAbA homology model. The SAP values at R 
= 5 Å are mapped onto the molecular surface of the mAbA homology model, where red regions 
represent hydrophobic and aggregation-prone regions and blue regions are hydrophilic and 
















Chapter 5. Investigating the photo degradation of rat growth hormone with 
extreme ultra-pressure liquid chromatography-mass spectrometry utilizing 














In the past three decades recombinant protein therapeutics have revolutionized the bearing of the 
modern medicine and commenced competent therapies for several diseases. Since 1982, when 
the first therapeutic protein- recombinant human insulin was introduced, the number of protein 
therapeutics in the global market have increased dramatically in number and their frequency of 
use.1,2 Protein therapeutics constituted 17% of new drugs approved by the FDA in 2005, and 
increased to 32% by 2011. The Global Protein Therapeutics and Devices Market is expected to 
grow at a compound annual growth rate of around 8.6% over the next decade to reach 
approximately $315.90 billion by 2025.3 The success of protein drugs over small-molecule drugs 
is attributed to several advantages such as 1) high specificity with low side effects, 2) well 
tolerated by the body, 3) clinical development and approval time can be shorter relative to small-
molecule drugs and 4) their distinctive structure and functions permit for comprehensive patent 
protection.1,2,4 Proteins are sensitive to various physical and chemical degradation pathways such 
as oxidation, deamidation, hydrolysis, aggregation, β-elimination, photochemical degradation, 
etc.5-7 Photochemical damage could occur after proteins are exposed to light during 
manufacturing, purification, storage, and drug administration.8  
In proteins, aromatic amino acids (Trp, Tyr, and Phe), and the disulfide bonds are more 
susceptible to photodegradation.8 Upon absorption of light, aromatic amino acids generate an 
excited singlet state, which can undergo intersystem crossing to the first excited fluoresce, triplet 
state, or eject an electron into the solution, yielding a solvated electron and an aromatic radical 
cation.8,9 The solvated electron can reduce the disulfide bond to yield a disulfide radical anion 
which, on further proton addition and cleavage, produces a thiol and thiyl radical.9 Thiyl radicals 




light (λ = 254 nm). Eventually, thiyl radicals can recombine to native or scrambled disulfide 
bonds, disproportionate into thiol and thioaldehyde.9-12 These initially formed sulfur-bearing 
residues have been shown to undergo a series of reactions ultimately leading to the formation of 
dithiohemiacetals, cyclic thioethers and cyclic vinylthioethers.13 But, under aerobic conditions, 
thiyl radicals can react with oxygen to form thiyl peroxyl radicals, which eventually convert into 
sulfinic, sulfenic, or sulfonic acids.10 The protein and peptide thiyl radicals can also participate in 
intramolecular hydrogen atom (H) abstraction reactions with adjacent side chain C-H or alpha 
carbon hydrogen (αC-H) bonds, generating intermediary carbon centered (C•) radicals. The C• 
may subsequently involve in cross-linking, fragmentation and oxidation pathways.12-14 
Specifically with αC-H bonds, such reversible H-atom transfer can induce epimerization.15  
Proteins are large complex molecules, often consisting of heterogeneous mixtures. A comparison 
between small-molecule and protein drugs makes it clear as to why comprehensive analysis of 
proteins is challenging.16-18 For example aspirin, which is considered as a small-molecule 
measures just 180 Da and has 21 atoms. In contrast, a typical monoclonal antibody measures 
150,000 Da, contains ~ 500 amino acids comprising of ca. 20,000 atoms. The myriad of 
degradation products that can be formed in proteins further increases the complexity of their 
analysis.17,18 
To reduce the complexity of these samples, analytical methods often rely on reversed phase 
liquid chromatography (RPLC) separations preceding the identification by mass spectrometry 
(MS).19 The analytical work flow of proteins typically involves an enzymatic digestion step 
which generates a mixture of peptides.17-19 The various photodegradation products previously 
described were identified by LC-MS analysis in model peptides and proteins such as insulin, and 




identification of various modifications, analytical scientists frequently encounter the problem of 
partial or complete co-elution which can cause incomplete profiling of degradation products. 
Complete resolution of the analytes can be achieved by development of more efficient LC 
techniques. 
Peak capacity is the best measure of the performance of a gradient separation. Peak capacity is 
defined as the maximum number of components that can be resolved within a given separation 
window.20 This can be achieved by extending the gradient time, but the increase in peak capacity 
with increase in gradient time reaches plateau as the gradient becomes shallow. Alternate to 
extending gradient time is increasing the length of the column packed with small particles. In 
general, peak capacity is proportional to the square root of length of the column and inversely 
proportional to square root of diameter of the particles used for packing the column.21,22 One 
limitation using long columns packed with small particles is the pressure (more than 10,000 psi) 
that is needed to maintain a given linear velocity, which restricted the use of long column packed 
with sub-2 µm particles. In collaboration with Jorgenson group at UNC Chapel Hill, Stobaugh 
group at The University of Kansas has built a capillary-based chromatography system with 
operational capability over the 35-40 Kpsi range which we term as extreme ultra-pressure liquid 
chromatographic (XUPLC) system.23 In this study, we used XUPLC system to delineate the 
photodegradation of rat growth hormone (rGH) protein.         
5.2 Experimental methods 
5.2.1 Materials 
Optima-grade water, Optima-grade 0.1% formic acid in water, Optima-grade 0.1% formic acid in 




Scientific (Fairlawn, NJ, USA). HPLC-grade acetone was obtained from Sigma-Aldrich (St. 
Louis, MO, USA). 
5.2.2 Protein production 
The plasmid for rGH was provided by GenScript (New Jersey, USA). This plasmid was given to 
KanPro Research Inc. for expression of rGH. The plasmid was transfected into BL21 (DE3), a 
type of E. coli cells, which is mainly used for expression of various proteins. In brief, the E. coli 
cells were cultured in 10 ml lysogeny broth (LB) culture media with the antibiotics (kanamycin 
and chloramphenicol) for around 12 hours. This 10 ml culture was added to 1 L LB media and 
was placed in a shaking incubator at 37° C and 200 rpm with the antibiotics (kanamycin and 
chloramphenicol), until optical density of the media reached a value of 0.6. Isopropyl β-D-1-
thiogalactopyranoside (IPTG) (1 mM) was added to the LB media and incubation was continued 
for 4 hours. Cells were centrifuged at 4,000 rpm for 10 mins and the cell pellet was suspended in 
the lysis buffer (50 mM tris hydrochloride, 500 mM sodium chloride, pH 8). This mixture was 
then sonicated, until it was no longer viscous. Inclusion bodies of rGH were isolated by 
centrifuging at 19,500 rpm for 30 mins and were washed with water. These inclusion bodies 
were dissolved in the lysis buffer containing 6 M urea. The dissolved inclusion bodies were 
refolded by following proprietary procedures and dialyzed in a phosphate buffer saline (PBS) 
containing 88 mM mannitol. 
5.2.3 Photoirradiation 
The photoirradiation was carried out in a Rayonet photoreactor RPR-200 [Southern New 
England Ultra Violet Company (Branford, CT)] equipped with four 35 W low pressure mercury 




25 mM sodium phosphate buffer at pH 7.2. Samples were placed in quartz tubes, and saturated 
with Argon (Ar) prior to photoirradiation. Samples were irradiated for 30 mins. 
5.2.4 Reduction, alkylation and digestion 
For peptide mapping of the rat growth hormone (rGH), 200 μL of either the controls or the 
photo- irradiated samples were mixed with 100 µL of 50 mM ammonium bicarbonate buffer (pH 
8.2), 25 μL of guanidine hydrochloride solution (6 M, in ammonium bicarbonate buffer, 50 mM, 
pH 8.2) and 50 μL dithiothreitol solution (25 mM) for the reduction of the disulfide bonds. The 
mixtures were incubated at 50 °C for 30 mins. The thiolate groups of the reduced cysteine 
residues were then alkylated by the addition of 50 μL of iodoacetamide (100 mM). After 1 hour 
incubation in the dark at 37 oC, the protein was precipitated with 500 µL of 0.5 M perchloric 
acid, and centrifuged at 14,000 g for 10 mins at 4 oC. The resulting pellet was washed twice with 
milliQ water. Thereafter, the pellet was reconstituted in 200 µL of ammonium bicarbonate buffer 
(50 mM, pH 8.2). The digestion was performed by the addition of 10 µg of trypsin/chymotrypsin 
with a ratio [protein]: [trypsin] = 20 to each sample. After overnight incubation at 37 oC, the 
peptides were purified using Amicon ultra-0.5 centrifugal devices, equipped with 10 kDa cut-off 
membranes in order to separate undigested protein and trypsin/chymotrypsin from the proteolytic 
peptides.  
5.2.5 XUPLC using capillary columns 
The XUPLC (Fig. 2) system was assembled around a nanoAcquity UPLC and Xevo G2 QTof 
mass spectrometer (Waters Corporation, Milford, MA) equipped with a nano electrospray 
interface (nESI). Detailed description on assembling the XUPLC system was described by 




and V4), a pneumatic amplified pump (Haskel pump), gradient storage loop (GSL), series of tees 
(T1, T2, T3 and T4), a capillary chromatography column, connectors and tubings.  
The XUPLC requires loading the GSL with solvent program that performs various functions. 
Optima-grade water with 0.1% formic acid and Optima-grade water with 0.1% formic acid was 
used as Mobile phase A (A) and Mobile phase B (B), respectively. The solvent gradient program 
was operated in a last in first out format (LIFO). The operation of the XUPLC system can be 
divided into 9 stages, as shown in Table 1. The solvent gradient program in Table 1, results in 
flowing approximately 10 µL of 7% B through the capillary column before meeting a gradient 
with linear increase in % B from 7% - 45%. This was followed by a series of brief steps such as: 
a brief isocratic hold at 45% B for 0.1 mins, a rapid surge to 70% B, and a return to 7% B. The 
gradient loading was followed by sample loading. Through- out the gradient and sample loading 
steps V2, V3, V4 were always open and V1 was closed allowing the flow of the solvents into the 
GSL. After the sample loading step, data acquisition step was initiated by opening V1 and 
closing V2, V3 and V4, which enabled the Haskel pump to push the solvent and the sample in 
the GSL onto the capillary column for chromatographic separation and eventually into Xevo 
QTof for mass spectrometric analysis. The column was housed in a column-heating device 
maintained at 45 oC. 
5.2.6 Ultra-Performance Liquid Chromatography utilizing a commercial 
column   
Liquid chromatography-mass spectrometry (LC-MS) analyses of the peptide maps were 
performed on a nanoAcquity ultra performance liquid chromatography system (Waters 




Waters Trap Column (2G-V/MTrap, 180 µm x 20mm, 5 µm) connected to an analytical 
nanoAcquity ultra performance Waters column (CSH C18, 75 µm x 250 mm, 1.7 µm). Mobile 
phases consisted of water/acetonitrile/formic acid at a ratio of 99%, 1%, and 0.08% (v:v:v) for 
solvent A and a ratio of 1%, 99%, and 0.06% (v:v:v) for solvent B. The injected sample was first 
loaded onto a trapping column at 4 µL/min for 3 min with 97% of solvent A and 3% of solvent 
B. After 3 min, the peptides were directed toward the analytical column and were separated with 
a linear gradient (3%-35% of solvent B within 50 mins) delivered at a rate of 0.3 µL/min.  
5.2.7 Nano electrospray Ionization Time-of-Flight MS and MS/MS Analysis 
Mass spectrometry was performed on a Waters Xevo-G2 (Waters Corporation, Milford, MA) 
.The outlet of the RPLC column was connected to a qTOF Premier (Waters Corp) through a 
stainless steel LC-MS (Thermo Scientific) emitter (50 mm x 30 µm I.D x 150 µm O.D) and each 
emitter was inserted into a micro sleeve (180 µm I.D) to facilitate installation on to a nanospray 
emitter tip (Waters Corp). The system was operated in the positive mode with spray voltage 
(+2.7kV) applied on a nanoflow emitter. The desolvation gas flow and the desolvation 
temperature were set to 1000 L/h and 100 oC, respectively. The cone gas flow was set to 25 L/h 
and a source temperature of 100 oC. The capillary voltage and cone voltage were set to 2,700 and 
45 V, respectively. The Xevo-G2 acquisition rate was set to 0.5 s with a 0.0 s interscan delay. 
The instrument was operated in the MSE mode, with the first resolving quadrupole in a wide pass 
mode with the collision cell operating with different alternating energies. To acquire the non-
fragmented MS spectrum, the collision cell was operated at 3 eV and the fragmented MS/MS ion 




The MS and MS/MS spectra obtained by the Q-TOF G2 were analyzed with MassLynx program 
V4.1 from Waters Corporation. Furthermore, the LC-MS/MS data was processed using Byonic 
Software. The rGH digests were searched against a database with the amino acid sequence of the 
protein using 10 ppm and 20 ppm mass tolerance parameters for precursor and fragment ions, 
respectively. 
5.3 Results 
Here we define two terms that are used throughout the next sections from this point forward. 
First, the term “control” refers to an rGH sample which was directly diluted from the stock 
solution. Second, “irradiated” sample refers to an rGH sample, which was exposed to UV light (λ 
= 254 nm). 
5.3.1 XUPLC separation of control rGH digest 
As noted previously, unloading of the contents in the GSL (solvent gradient + sample) as shown 
in Table 1 happened over the data acquisition (295 mins) step with a flow rate of 0.29 µL/min. 
Fig. 3 shows a typical chromatogram for a control rGH digest. Data analysis with the Byonic 
software program indicated ~ 92% protein coverage. The retention time (tR) of the first identified 
peak was at 41 mins (Fig. 3), with all identified peptides listed in Table 2. The peaks eluting 
prior to this peptide (41 mins) were not identified and appeared to be late-eluting peaks from the 
previous injection. The retention time values were highly reproducible with RSD < 0.15 (n=3), 
except for some of the peptides. The first two peptides identified (Fig. 3 insert) which eluted at tR 
41.3 min and 45.4 min represent pre-irradiation Met oxidation (Met 124) products. In addition, 




5.3.2 UPLC separation of control rGH digest   
A chromatogram resulting from the separation of a control rGH digest using the UPLC system is 
shown in Fig. 4. Data analysis with the Byonic software program indicated ~ 92% protein 
coverage. All the UPLC separations were conducted in the non-trapping mode, which facilitates 
a better comparison with the XUPLC separations. The elution of the first identified peak 
occurred at tR = 32.33 min, with all identified peptides listed in Table 3. The retention time 
values were reproducible with RSD < 0.62 (n=3). Peptides with oxidized Met residues (pre-light 
exposure) co-eluted in a single peak (Fig. 4 insert).  
5.3.3 XUPLC separation of irradiated rGH  
To examine the utility of XUPLC in analyzing protein degradation and identification of 
degradation products, rGH was exposed to UV light (λ = 254 nm), followed by reduction, 
alkylation and enzymatic digestion. The peptides resulting from the enzymatic digestion of 
control and irradiated rGH were separated using the XUPLC setup, which resulted in the 
chromatograms shown in Fig. 5. Fig.5 displays some interesting features: some of the peaks in 
the irradiated sample decreased, with newly formed products appearing as new peaks (Fig.5 
insert). Focusing on the peaks in the insert of Fig.5, degradation of peptide F184AESSCAF191, 
eluting at tR = 142.35 min, resulted in the formation of two chromatographically resolved 
products eluting at tR = 137.7 and 142.35 min. MS analysis revealed that the two 
chromatographically resolved products were isobaric (both the products has the same mass) in 






5.3.4 MS/MS analysis of photo degradation of products 
The C-terminal region of rGH contains one intra-chain disulfide bond between Cys 181 and Cys 
189. As disulfide bonds undergo photo degradation upon exposure to light (especially λ = 254 
nm), thus it become of primary importance to identify the b and y ions, which allows us to 
discriminate between different photodegradation products. The MS/MS spectrum reported in Fig. 
7 provides evidence for the degradation of F184AESSCAF191 to F184AESSC(-2)AF191. The ions 
b3+, b4+, and b5+ indicate that a part of sequence is unmodified on light exposure, where m/z 
522.21 corresponds to the singly charged ion of FAESS. Instead, the ions y5+ and y6+, despite 
their low intensity, provide the evidence that cysteine (Cys 189) degraded to form an ene-thiol, 
which was eventually alkylated with iodoacetamide. For example, comparison of b6+, b7+, y5+, 
and y6+ ions between Fig.7 (MS/MS of Cys 189-containing peptide after irradiation) vs Fig.8 
(MS/MS of Cys 189-containing peptide before irradiation) where all these ions show a mass 
difference of 2 Da further confirm the degradation of Cys 189 to the ene-thiol.  
5.4 Discussion 
Complete identification of the degradation products of proteins is essential to elucidate the 
complex degradation pathways. To reduce the complexity of these samples, analytical methods 
depend on reverse phase liquid chromatography (RPLC) for the separation of various chemical 
entities before their identification using mass spectrometry (MS). RPLC-MS analysis has 
become a preferred analytical tool for the identification of protein and their variants, location of 
post-translational modifications (PTMs) and confirm protein sequences.25 Although, RPLC-MS 
is widely used in multiple investigations, frequently this analysis faces the problem of partial or 




degradation products that are formed. This can be resolved by developing more efficient LC 
techniques that will allow introducing better resolved chemical entities into the MS and increase 
degradation product identification.22-24 The efficiency of LC gradient separation can be extended 
by increasing the length of the column.23 In this study, emphasis is placed on analyzing 
photoinduced degradation of rGH using XUPLC system and comparing the results obtained by 
XUPLC to those obtained by using UPLC system. 
5.4.1 Comparison between XUPLC and UPLC separations of rGH digests 
By comparing chromatograms in Fig. 3 and Fig. 4, we can conclude that there is an overall 
increase in resolution between the peaks during XUPLC separations compared to the UPLC 
separations. Of particular interest are inserts in Fig.3 and Fig.4 where early eluting Met oxidation 
products are identified. During XUPLC analysis the Met oxidation products 
[M(O)QELEDGSPR] elute as two chromatographically resolved peaks. Resolution of Met 
oxidation products into two separate peaks can be rationalized by the formation of new 
stereocenter of either R or S configuration during the oxidation process, leading to formation of 
diasteriomeric peptides.26 When the same samples underwent UPLC analysis the Met oxidation 
products co-eluted. The increased overall resolution during XUPLC analysis (118 cm column 
was used) when compared to UPLC analysis (25 cm column was used) can be explained by the 
large in theoretical plate count that are resultant of increase in length of the column.  
In addition, similar conclusions can be made on comparison of Fig. 5 and Fig. 6, where irradiated 
rGH digests subjected to XUPLC analysis exhibited greater efficiency in separating 
photodegradation products into two chromatographically separated peaks, whereas with the 




chemistry of photo-induced chemical degradation knowledge, the products were identified to be 
resultant of degradation of disulfide linkages (Cys 181-Cys 189). Even though these products 
were isobaric with same MS/MS fragmentation, they eluted as two separate peaks which are 
assigned as diastereomerically related cis/trans isomers; nonetheless, with the current data it is 
not possible to decide specific assignments. The formation of cis/trans products can be explained 
through the reaction scheme presented in Fig.9. Intra-chain disulfide bonds in UV irradiated (λ = 
254 nm) rGH undergo homolytic cleavage forming a pair of thiyl radicals. The pair of thiyl 
radicals formed undergoes a disproportionation leading to the formation of thioaldehyde and 
thiol products. The resulting thioaldehyde products are known to participate in tautomeric 
equilibria to form ene-thiols.10-14          
5.5 Conclusions 
An XUPLC system with pressure capabilities upto 35-40 Kpsi and connected with capillary 
columns ranging 118 cm with sub-2 µm particles was used for profiling photo-induced 
degradation of rGH. Comparison of XUPLC separations with UPLC separations which were 
achieved with columns ranging 25 cm showed significant increase in resolution. Analysis of 
photo-induced degradation of rGH using XUPLC system resolved isobaric cis/trans 
diasteriomeric products into two chromatographically resolved peaks, which were unresolved on 
subjecting to UPLC separations. Chromatographic systems employing long capillary columns 
which are operated under high pressure will be an indispensable tool for analysis of complex 
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Table 1. Detailed report of solvents loaded into the gradient storage loop together with a 





# Peptide       m/z R.T (min) S.D (min) %RSD 
1 M(O)QELEDGSPR 1117.52 41.27 0.112 0.11 
2 M(O)QELEDGSPR 1117.52 45.39 0.107 0.11 
3 FDANMR 753.33 53.59 0.181 0.337 
4 AYIPEGQR 933.47 59 0.108 0.183 
5 SETIPAPTGK 1000.53 65.39 0.061 0.093 
6 QELEDGSPRI 1030.48 65.39 0.072 0.11 
7 SDDALLK 648.69 66.14 0.127 0.192 
8 IGQILK 671.8 66.14 0.115 0.173 
9 MQELEDGSPR 1161.49 67.42 0.072 0.106 
10 HQLAADTY 803.4 70.75 0.111 0.156 
11 QTYDKF 801.87 70.84 0.075 0.105 
12 AQHLHQLAADTY 1367.61 75.94 0.042 0.055 
13 TNSLM 565.26 78.18 0.139 0.177 
14 GLL 302.2 102.99 0.171 0.166 
15 RFAESSCAF 1074.46 104.79 0.087 0.083 
16 TDMELLR 877.44 125.65 0.11 0.087 
17 GPVQF 547.28 125.65 0.135 0.107 
18 CFSETIPAPTGK 1307.6 128.29 0.114 0.088 
19 SIQNAQAAF 949.47 131.36 0.122 0.092 
20 SSLF 453.51 138.84 0.167 0.12 
21 SDDALL 633.31 139.75 0.168 0.12 
22 FAESSCAF 918.344 142.35 0.123 0.086 
23 IGQIL 543.35 144.48 0.164 0.113 
24 TNSLM(O)F 728.33 152.39 0.197 0.11 
25 IFTNSL 694.37 156.92 0.112 0.071 
26 LIQSW 589.71 157.77 0.137 0.086 
27 SLLL 445.58 176.3 0.246 0.139 
28 YSIQNAQAAF 1188.56 180.8 0.174 0.096 
29 TNSLMFGTSDR 1228.56 187.56 0.193 0.102 
30 DLHKAETY 975.46 191.2 0.127 0.066 
31 TDMELL 721.34 196.96 0.25 0.126 
32 LGPVQF 660.37 198.36 0.193 0.097 
33 SCF 413.37 198.78 0.302 0.151 
34 FSLL 479.28 211.5 0.217 0.102 
35 DLEEGIQAL 987.49 226.68 0.214 0.094 
36 EEGIQAL 760.38 232.67 0.217 0.093 
37 LIQSWL 759.44 232.67 0.217 0.093 





Table 2. Control rGH digest eluted using XUPLC setup. Retention reproducibility was 
calculated using three independent injections of the digest. R.T represents retention time, m/z 



















#       Peptide       m/z RT 
(min) 
SD (min) % RSD 
1 M(O)QELEDGSPR 1117.52 32.33 0.134 0.29 
2 M(O)QELEDGSPR 1117.52 32.33 0.134 0.29 
3 AYIPEGQR 933.47 35.2 0.195 0.553 
4 FDANMR 753.33 35.2 0.169 0.48 
5 SETIPAPTGK 1000.53 35.91 0.193 0.537 
6 MQELEDGSPR 1161.49 35.91 0.197 0.548 
7 HQLAADTY 918.4 35.91 0.191 0.531 
8 AQHLHQLAADTY 1367.61 35.91 0.218 0.607 
9 QELEDGSPRI 1030.48 35.91 0.179 0.498 
10 SDDALLK 648.69 36.6 0.123 0.336 
11 QTYDKF 801.87 37.2 0.231 0.62 
12 IGQILK 671.8 38.01 0.198 0.507 
13 RFAESSCAF 1074.46 41.42 0.181 0.436 
14 TNSLM 565.26 42.2 0.186 0.44 
15 CFSETIPAPTGK 1307.6 43.28 0.174 0.402 
16 TDMELLR 877.44 45.51 0.157 0.344 
17 SIQNAQAAF 949.47 46.49 0.141 0.303 
18 FAESSCAF 918.344 47.68 0.122 0.255 
19 GPVQF 547.28 47.68 0.124 0.26 
20 GLL 302.2 47.68 0.174 0.364 
21 SSLF 453.51 50.82 0.143 0.299 
22 SDDALL 633.31 50.82 0.186 0.495 
23 IGQIL 543.35 50.82 0.152 0.482 
24 SLLL 445.58 50.82 0.252 0.394 
25 TNSLM(O)F 728.33 51.23 0.237 0.41 
26 LIQSW 646.35 51.23 0.247 0.262 
27 IFTNSL 694.37 51.23 0.202 0.42 
28 DLHKAETY 975.46 51.4 0.135 0.262 
29 TNSLMFGTSDR 1228.56 52.31 0.22 0.42 
30 YSIQNAQAAF 1112.56 52.31 0.246 0.47 
31 LGPVQF 660.37 54.91 0.129 0.234 
32 TDMELL 721.34 57.41 0.143 0.249 
33 SCF 413.37 57.45 0.174 0.302 
34 DLEEGIQAL 987.49 59.38 0.122 0.205 
35 FSLL 479.28 60.39 0.18 0.298 
36 EEGIQAL 760.38 61.34 0.181 0.295 
37 LIQSWL 759.44 61.34 0.175 0.285 





Table 3. Control rGH digest eluted using UPLC setup. Retention reproducibility was calculated 
using three independent injections of the digest. R.T represents retention time, m/z represents 






















1     MFPAMPLSSL    FANAVLRAQH    LHQLAADTYK    EFERAYIPEG    QRYSIQNAQA   50 
51   AFCFSETIPA       PTGKEEAQQR    TDMELLRFSL      LLIQSWLGPV   QFLSRIFTNS      100 
101  LMFGTSDRVY   EKLKDLEEGI     QALMQELEDG     SPRIGQILKQ    TYDKFDANMR 150 
151  SDDALLKNYG   LLSCFKKDLH    KAETYLRVMK     CRRFAESSCA   F                          191 
Figure 1. Sequence of rGH. Met residues are colored red and the two intra-chain disulfide 

















Figure 2. Schematic representation of the liquid flow path for the XUPLC add-on assembled 
around nanoAcquity UPLC and Xevo G2 ESI QTof MS. T1-T4 represent micro-volume 
connectors (tee), V1 represent 10 Kpsi air actuated on/off valves, V2-V4 represent 40 Kpsi air 
actuated on/off valves, A, B, E, F and H represent fused silica tubing, C-D represent Ni-clad 









   
Figure 3. XUPLC separation of control rGH digest, with insert showing oxidation of Met 


































   
Figure 5. XUPLC separation of photo-induced (red) vs control rGH (black) digest, insert shows 
photodegradation products identified, which are isobaric (same mass). Arrows indicate tryptic 












   
Figure 6. UPLC separation of photo-induced (red) vs control rGH (black) digest, insert shows 
photodegradation products identified. Arrows indicate tryptic peptides that exhibited decrease in 










   
Figure 7. Collision-induced dissociation mass spectrum of the peptide FAESSC (-2) AF 
resulting from the digestion of rGH exposed to λ = 254 nm, which contains Cys 181 that 






Figure 8. Collision-induced dissociation mass spectrum of the peptide FAESSCAF resulting 
from the digestion of control rGH that contains Cys 181, which is sensitive to photo-induced 













Figure 9. Mechanism showing the formation of rGH photodegradation products. Thioaldehyde 
and thiol products are formed from corresponding thiyl radicals generated due to photolysis of 
disulfide bonds. Tautomerization of thioaldehyde leads to cis/trans ene-thiols and alkylation with 







































6.1 Summary and conclusions 
The Protein therapeutics encounter various types of stress during production, processing, 
shipping and administration and hence are susceptible to a number of physical and chemical 
instability such as aggregation, oxidation, photodegradation, etc.1-3 The aftermath of physical and 
chemical protein instability can include loss of potency and immunogenicity.4,5 Previously, the 
immunogenicity of protein therapeutics was majorly associated with the formation of protein 
aggregates,6-8 but in recent years there is an increase in evidence showing the role of chemical 
modifications in causing immunogenicity.4,5 To fully understand the consequences of chemical 
degradation of protein therapeutics, the range and nature of chemical modifications formed 
should be characterized to the max. The comprehensive characterization of degradation products 
also requires development of novel methodologies to complement the existing analytical 
techniques. Therefore, the aim of this dissertation was to further investigate the mechanisms of 
chemical and physical degradation of proteins, which can assist in development of stable protein 
therapeutics. 
Chapter 2 describes a rapid screening methodology to identify protein oxidation by monitoring 
Tyr and Phe oxidation. The oxidation of Tyr and Phe was first monitored by fluorogenic 
derivatization using fluorescence spectroscopy and complementary LC-MS analysis was done to 
identify the extent of methionine oxidation in oxidized proteins. The Fluorogenic derivatization 
technique was easily adapted to a 96-well plate, in which several protein formulations can be 
screened in a short time. Representatively for hGH, we showed that the formation of 
benzoxazole parallels the oxidation of Met to methionine sulfoxide which enables estimation of 




Chapter 3 illustrates the effect of various excipients (L-Arg, L-Leu, L-Met, glucose and sucrose) 
on the extent and site-specificity of D-amino acid formation in UV light exposed mAb 
formulations. The mAb-containing formulations were photo-irradiated at λ = 254 nm and λmax = 
305 nm, followed by fractionation of aggregate and monomer fractions using size exclusion 
chromatography. Both aggregate and monomer fractions collected from all the formulations 
showed the formation of D-Glu and D-Val, whereas the formation of D-Ala was  limited to the 
aggregate fraction collected from an L-Arg-containing formulation. Interestingly, quantitative 
analysis revealed higher yields of D-amino acids in the L-Arg-containing formulation. This can 
be rationalized by an increase in mAb flexibility in the CH1 and CH2 domains in the presence of 
L-Arg, which can increase the probability of D-amino acid formation. However, quantitative 
analysis failed to detect a clear trend of D-amino acid accumulation in aggregates, suggesting 
that the levels of D-amino acids generated under our experimental conditions do not generally 
lead to an enhanced potential for aggregate formation. 
Chapter 4 compares the conformational stability, backbone flexibility, and aggregation 
propensity of monomer and dimer fractions of an IgG1 monoclonal antibody (mAb) generated 
upon UVA light exposure for upto 72 hours collected by preparative size-exclusion 
chromatography (SEC), compared to unstressed control. UVA light exposure induced covalent 
aggregation, fragmentation, and extensive oxidation of specific methionine residues (Met 257, 
Met 433, and Met 109) in both size fractions identified by reverse phase chromatography 
coupled to mass spectrometry. Compared to unstressed mAb, the monomer and dimer 
fractionated from 72 hours UVA light exposed mAb had decreases in thermal melting 
temperatures (Tm1) by 1.38 
oC and 1.37 oC, respectively as measured by differential scanning 




monomer loss and aggregation on accelerated storage at 35 oC. Hydrogen/deuterium exchange 
mass spectrometry identified local segments with increased flexibility in CH2 and CH3 domains 
of both size fractions, and decreased flexibility in few segments of Fab and CH1 domains in the 
dimer fraction. Segment 247-256 in heavy chain, an established aggregation hotspot in IgG1 
mAbs had large increase in flexibility in both size fractions compared to unstressed mAb.  
Chapter 5 outlines the use of a XUPLC system with pressure capabilities up to 38 Kpsi to 
improve the efficiency of one-dimensional separations using capillaries of 118 cm packed with 
sub-2 µm particles. A comparative analysis between XUPLC separations (using 118 cm length 
column) and commercial UPLC column (25 cm in length) revealed significant increase in 
resolution during the gradient separation. XUPLC analysis of photochemical degradation of rGH 
showed well-resolved isobaric cis/trans diastereomerically related ene-thiols, which co-eluted 
during UPLC analysis. Through this study we have demonstrated the capability of the XUPLC 
system in investigating complex chemical degradation problems.   
6.2 Future directions 
As a continuum, fluorogenic derivatization can be developed into a high-throughput technique 
where oxidative degradation can be quantified for multiple formulations. The consequences of 
chemical degradation can include loss of potency and immunogenicity.4-7 Using this fluorogenic 
derivatization technique in pharmaceutical industries and pharmacies can limit the supply of 
degraded protein therapeutic to the patient. 
Almost all the studies use the whole protein molecule to identify the immunogenic potential of 
degraded protein therapeutic which makes it difficult to deduce which immunogenicity of 




can help in identification of the immunogenic potential of a specific degradation products. This 
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